CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reimbursement Review Reports

Updates on CADTH reimbursement reviews are posted to this page. Reports are  searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them, and appropriate credit is given to CADTH.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Proyect name
Gynazole.1 Butoconazole nitrate Vaginal infection Do not list Complete June 30, 2004 January 26, 2005 SR0017-000
NovoMix 30 Insulin aspart/insulin aspart protamine Diabetes mellitus Do not list Complete October 13, 2005 April 26, 2006 SR0041-000
Fosavance 70/5600 Alendronate sodium / cholecalciferol Osteoporosis List in a similar manner to other drugs in class Complete December 18, 2008 June 17, 2009 SR0153-000
Abilify Aripiprazole Schizophrenia Do not list Complete November 6, 2009 April 27, 2010 SR0183-000
Abilify Aripiprazole Depression, Major Depressive Disorder Do not list Complete October 1, 2013 October 22, 2014 SR0354-000
Abilify Aripiprazole Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete March 29, 2011 July 18, 2011 SF0226-000
Abilify Maintena Aripiprazole Schizophrenia List with criteria/condition Complete January 6, 2014 December 19, 2014 SR0366-000
Abstral Fentanyl citrate Pain, breakthrough cancer pain Do not list Complete June 30, 2011 December 16, 2011 SR0240-000
Aclasta Zoledronic acid Osteoporosis List with clinical criteria and/or conditions Complete July 20, 2011 November 16, 2011 SF0242-000
Aclasta Zoledronic acid Osteoporosis, postmenopausal women List with clinical criteria and/or conditions Complete November 29, 2007 June 25, 2008 SR0114-000
Actemra Tocilizumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete January 30, 2012 July 19, 2012 SR0267-000
Actemra Tocilizumab Arthritis, polyarticular juvenile idiopathic List with criteria/condition Complete July 29, 2013 March 19, 2014 SR0343-000
Actemra Tocilizumab Arthritis, rheumatoid List with criteria/condition Complete March 3, 2014 February 19, 2015 SR0374-000
Actemra Tocilizumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete May 27, 2010 November 17, 2010 SR0201-000
Actemra tocilizumab Giant cell arteritis (GCA) Reimburse with clinical criteria and/or conditions Complete September 25, 2017 March 27, 2018 SR0534-000
Actikerall Fluorouracil and Salicylic Acid Hyperkeratotic actinic keratosis Reimburse with clinical criteria and/or conditions Complete August 31, 2016 March 22, 2017 SR0498-000
Adcirca Tadalafil Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete February 5, 2010 July 15, 2010 SR0197-000
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Withdrawn December 15, 2004 SR0027-000
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Do not list Complete April 13, 2004 November 24, 2004 SR0010-000
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder, Adult Do not list Complete November 29, 2007 June 25, 2008 SR0116-000
Adempas Riociguat Chronic thromboembolic pulmonary hypertension List with criteria/condition Complete September 30, 2013 July 17, 2014 SR0353-000
Adempas Riociguat Pulmonary arterial hypertension (WHO group 1) List with clinical criteria and/or conditions Complete June 25, 2015 December 17, 2015 SR0438-000
Adlyxine lixisenatide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete May 29, 2017 November 23, 2017 SR0520-000
Admelog Insulin lispro Cancelled SE0543-000
Advicor Niacin/lovastatin Hypercholesterolemia and mixed dyslipidemia List Complete October 18, 2005 April 26, 2006 SR0042-000
Aermony RespiClick fluticasone propionate Asthma Reimburse with clinical criteria and/or conditions Complete October 4, 2017 December 19, 2018 SR0539-000
Zenhale (inhalation aerosol) Mometasone furoate and formoterol Asthma Do not list Complete February 16, 2011 September 28, 2011 SR0225-000
Afinitor Everolimus Subependymal giant cell astrocytoma associated with tuberous sclerosis complex Do not list Complete March 19, 2014 April 15, 2015 SR0376-000
Afinitor Everolimus Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Do not list Complete March 8, 2013 September 25, 2013 SR0315-000
Aimovig erenumab Migraine Reimburse with clinical criteria and/or conditions Complete May 2, 2019 July 22, 2020 SR0578-000
Ajovy fremanezumab migraine Active June 3, 2020 SR0641-000
Akynzeo netupitant / palonosetron Nausea and vomiting (chemotherapy induced) prevention Reimburse with clinical criteria and/or conditions Complete December 8, 2017 June 20, 2018 SR0548-000
Aldurazyme Laronidase Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie Do not list Complete February 3, 2005 July 14, 2005 SR0032-000
Aloxi (capsule) Palonosetron Chemotherapy-induced nausea and vomiting Withdrawn February 6, 2015 SR0415-000
Aloxi (injection) Palonosetron hydrochloride Chemotherapy-induced nausea and vomiting Do not list at the submitted price Complete October 5, 2012 May 15, 2013 SR0293-000
Aloxi (capsule) Palonosetron hydrochloride Chemotherapy-induced nausea and vomiting Do not list Complete October 5, 2012 April 24, 2013 SR0294-000
Altace Plus Felodipine Ramipril/felodipine extended release Hypertension Do not list Complete June 22, 2006 November 15, 2006 SR0067-000
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled October 26, 2006 SR0083-000
Altace HCT Ramipril/hydrochlorothiazide Hypertension List Complete March 26, 2007 June 14, 2007 SR0095-000
Alvesco Ciclesonide asthma List Complete July 24, 2006 December 20, 2006 SR0074-000
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete February 28, 2006 September 27, 2006 SR0053-000
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete November 16, 2004 May 26, 2005 SR0024-000
Vocabria and Cabenuva cabotegravir sodium cabotegravir-rilpivirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete August 19, 2019 July 22, 2020 SR0628-000
Braftovi and Mektovi encorafenib and binimetinib Advanced Melanoma Active December 16, 2020 PC0232-000
Anoro Ellipta Umeclidinium/vilanterol Chronic obstructive pulmonary disease List with criteria/condition Complete February 26, 2014 January 15, 2015 SR0371-000
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete August 29, 2008 February 19, 2009 SR0144-000
Apprilon Doxycycline monohydrate Rosacea Do not list Complete April 27, 2012 March 27, 2013 SR0279-000
Aptiom Eslicarbazepine acetate Epilepsy, partial-onset seizures List with criteria/condition Complete August 15, 2014 April 16, 2015 SR0391-000
Aptivus Tipranavir HIV infection List with clinical criteria and/or conditions Complete December 15, 2005 May 17, 2006 SR0047-000
Arbesda RespiClick fluticasone propionate / salmeterol xinafoate Asthma Reimburse with clinical criteria and/or conditions Complete October 4, 2017 December 19, 2018 SR0540-000
Arnuity Ellipta Fluticasone furoate Asthma List with criteria/condition Complete June 26, 2015 December 17, 2015 SR0439-000
ASMANEX Mometasone furoate Asthma List Complete November 10, 2011 May 16, 2012 SR0258-000
Atectura Breezhaler indacaterol /mometasone furoate Asthma maintenance (adults, children 12 or older) Reimburse with clinical criteria and/or conditions Complete May 19, 2020 November 24, 2020 SR0646-000
Atripla Efavirenz, emtricitabine, tenofovir disoproxil fumarate HIV List with clinical criteria and/or conditions Complete October 30, 2007 April 17, 2008 SR0111-000
Aubagio Teriflunomide Multiple sclerosis, relapsing-remitting Do not list at the submitted price Complete August 28, 2013 June 18, 2014 SR0350-000
Somatuline Autogel Lanreotide acetate Acromegaly List in a similar manner to other drugs in class Complete February 20, 2007 July 19, 2007 SR0091-000
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete August 24, 2004 January 20, 2005 SR0019-000
Axert Almotriptan Migraine List in a similar manner to other drugs in class Complete December 24, 2003 May 27, 2004 SR0005-000
Azarga Brinzolamide and timolol maleate suspension Glaucoma and ocular hypertension List in a similar manner to other drugs in class Complete August 28, 2009 February 18, 2010 SR0173-000
Azilect Rasagiline mesylate Parkinson's disease Do not list Complete September 1, 2006 March 28, 2007 SR0073-000
Azilect Rasagiline mesylate Parkinson?s disease Complete March 10, 2009 SF0161-000
Banzel Rufinamide Lennox-Gastaut syndrome List with clinical criteria and/or conditions Complete September 20, 2011 March 15, 2012 SR0252-000
Baqsimi glucagon Severe hypoglycemic reactions Reimburse with clinical criteria and/or conditions Complete July 24, 2019 January 22, 2020 SR0626-000
Baraclude Entecavir Hepatitis B (chronic) List with clinical criteria and/or conditions Complete December 12, 2006 November 28, 2007 SR0089-000
Basaglar Insulin glargine Diabetes mellitus, type 1; diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete October 5, 2015 April 14, 2016 SE0451-000
Benlysta Belimumab systemic lupus erythematosus Do not reimburse Complete May 29, 2019 April 22, 2020 SR0616-000
Benlysta Belimumab Systemic lupus erythematosus Do not list Complete September 19, 2011 April 25, 2012 SR0251-000
Beovu brolucizumab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete September 26, 2019 May 21, 2020 SR0632-000
Biktarvy bictegravir/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete April 30, 2018 October 25, 2018 SR0567-000
Inflectra (Subsequent Entry Biologic) Infliximab Crohn’s disease and Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete April 12, 2016 October 25, 2016 SE0483-000
Botox OnabotulinumtoxinA Urinary incontinence List with criteria/condition Complete November 25, 2013 November 12, 2014 SR0362-000
Botox onabotulinumtoxinA Migraine, chronic Reimburse with clinical criteria and/or conditions Complete November 2, 2018 October 17, 2019 SR0584-000
Botox OnabotulinumtoxinA Neurogenic detrusor overactivity List with clinical criteria and/or conditions Complete January 31, 2012 July 19, 2012 SR0268-000
Botox OnabotulinumtoxinA Migraine Do not list Complete August 15, 2013 May 28, 2014 SR0345-000
Braftovi encorafenib Metastatic colorectal cancer Active December 16, 2020 PC0233-000
Ultibro Breezhaler Indacaterol/glycopyrronium Chronic obstructive pulmonary disease List with criteria/condition Complete February 3, 2014 December 19, 2014 SR0369-000
Enerzair Breezhaler indacaterol glycopyrronium mometasone furoate Asthma maintenance, adults Reimburse with clinical criteria and/or conditions Complete May 19, 2020 November 24, 2020 SR0645-000
Brenzys Etanercept Rheumatoid arthritis, Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete April 20, 2016 October 25, 2016 SE0485-000
Breo Ellipta fluticasone furoate/vilanterol Asthma Withdrawn May 2, 2018 SR0568-000
Breo Ellipta Fluticasone Furoate and Vilanterol (as trifenatate) Asthma List with clinical criteria and/or conditions Complete August 10, 2015 February 18, 2016 SR0442-000
Breo Ellipta fluticasone furoate/vilanterol COPD Withdrawn June 28, 2017 SR0524-000
Breo Ellipta Fluticasone furoate /vilanterol Chronic Obstructive Pulmonary Disease (COPD) List with criteria/condition Complete October 29, 2013 August 18, 2014 SR0358-000
Brilinta ticagrelor Prevention of atherothrombotic events with history of myocardial infarction Reimburse with clinical criteria and/or conditions Complete February 18, 2016 August 25, 2016 SR0474-000
Brilinta Ticagrelor Acute coronary syndromes Do not list Complete June 1, 2011 December 16, 2011 SR0234-000
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled June 8, 2010 SR0203-000
Brineura cerliponase alfa Neuronal Ceroid Lipofuscinosis Type 2 Reimburse with clinical criteria and/or conditions Complete July 31, 2018 May 23, 2019 SR0574-000
Brivlera Brivaracetam Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete April 19, 2016 January 25, 2017 SR0484-000
BuTrans Buprenorphine transdermal patch Pain, moderate intensity persistent pain Do not list Complete May 9, 2011 September 28, 2011 SR0233-000
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled October 15, 2010 SR0211-000
Byetta Exenatide Diabetes mellitus, type 2 Do not list Complete August 23, 2011 July 19, 2012 SR0246-000
Bystolic Nebivolol Hypertension Do not list at the submitted price Complete February 4, 2013 July 18, 2013 SR0307-000
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete September 13, 2019 August 26, 2020 SR0633-000
Caduet Amlodipine besylate/ atorvastatin calcium Hypertension/ Dyslipidemia List with clinical criteria and/or conditions Complete December 15, 2005 May 17, 2006 SR0048-000
Campral Acamprosate calcium Alcohol Abstinence Complete July 22, 2008 SF0143-000
Campral Acamprosate calcium Alcohol Abstinence List with clinical criteria and/or conditions Complete August 29, 2007 March 27, 2008 SR0108-000
Cayston Aztreonam for inhalation solution Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections List with clinical criteria and/or conditions Complete December 2, 2010 July 18, 2011 SR0220-000
Celsentri Maraviroc HIV Withdrawn November 2, 2007 SR0113-000
Celsentri Maraviroc HIV List with clinical criteria and/or conditions Complete May 7, 2008 November 12, 2008 SR0136-000
Celsentri Maraviroc HIV infection Do not list Complete December 8, 2010 July 18, 2011 SR0221-000
Cerdelga Eliglustat Gaucher disease Reimburse with clinical criteria and/or conditions Complete January 20, 2017 July 26, 2017 SR0511-000
Champix Varenicline tartrate Smoking-cessation List with clinical criteria and/or conditions Complete March 21, 2007 August 16, 2007 SR0094-000
Cimzia Certolizumab pegol Arthritis, rheumatoid Do not list Complete September 3, 2009 May 27, 2010 SR0175-000
Cimzia Certolizumab pegol Arthritis, psoriatic List with criteria/condition Complete September 2, 2014 April 17, 2015 SR0394-000
Cimzia certolizumab pegol Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete May 13, 2019 November 20, 2019 SR0587-000
Cimzia Certolizumab pegol Ankylosing spondylitis List with criteria/condition Complete June 23, 2014 April 17, 2015 SR0385-000
Cinqair reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete October 24, 2018 March 27, 2019 SF0591-000
Cinqair Reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete August 4, 2016 March 22, 2017 SR0495-000
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Do not list Complete June 8, 2006 January 24, 2007 SR0064-000
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Withdrawn August 3, 2005 SR0039-000
Ciprodex Ciprofloxacin hydrochloride & dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute List with clinical criteria and/or conditions Complete June 15, 2007 October 18, 2007 SF0101-000
Ciprodex Ciprofloxacin hydrochloride and dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute Do not list Complete June 11, 2004 January 26, 2005 SR0014-000
Combigan Ophthalmic Solution Brimonidine tartrate/timolol maleate Glaucoma List with clinical criteria and/or conditions Complete December 15, 2003 May 27, 2004 SR0001-000
COMPLERA Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate HIV infection List Complete October 19, 2011 April 19, 2012 SR0256-000
Constella Linaclotide Irritable bowel syndrome with constipation Do not list Complete December 17, 2014 September 23, 2015 SR0409-000
Contrave naltrexone hydrochloride and bupropion hydrochloride Chronic weight management in adults Do not reimburse Complete May 1, 2019 May 27, 2020 SR0610-000
Copaxone Glatiramer acetate Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis Do not list Complete April 29, 2009 November 25, 2009 SR0164-000
Cortiment Budesonide Ulcerative Colitis Do not reimburse Complete May 24, 2016 March 22, 2017 SR0491-000
Corzyna ranolazine Stable angina pectoris, adults Active August 17, 2020 SR0655-000
Cosentyx Secukinumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete February 19, 2016 August 23, 2016 SR0476-000
Cosentyx Secukinumab Plaque psoriasis List with criteria/condition Complete December 8, 2014 October 28, 2015 SR0407-000
Cosentyx Secukinumab ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete February 19, 2016 August 23, 2016 SR0475-000
Nucynta CR Tapentadol Pain, moderate to moderately severe Do not list Complete February 1, 2011 September 28, 2011 SR0224-000
Cresemba isavuconazole Treatment of invasive aspergillosis and mucormycosis Reimburse with clinical criteria and/or conditions Complete November 2, 2018 May 15, 2019 SR0586-000
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Reimburse with clinical criteria and/or conditions Complete July 23, 2019 May 27, 2020 SR0602-000
Cubicin Daptomycin Skin and skin structure infections & bacteremia Do not list Complete March 6, 2008 September 24, 2008 SR0127-000
Cuvposa glycopyrrolate chronic severe drooling, neurologic (pediatric) Do not reimburse Complete May 31, 2019 June 24, 2020 SR0613-000
Cymbalta Duloxetine hydrochloride Depressive, Major Disorder (MDD) Do not list Complete February 8, 2008 August 14, 2008 SR0125-000
Cymbalta Duloxetine hydrochloride Pain, Neuropathic, Diabetic List with clinical criteria and/or conditions Complete February 8, 2008 August 14, 2008 SR0126-000
Cystadrops cysteamine Corneal cystine crystal deposits Reimburse with clinical criteria and/or conditions Complete December 10, 2018 June 18, 2019 SR0595-000
Daklinza daclatasvir Hepatitis C, Chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 19, 2016 SF0467-000
Daklinza Daclatasvir Hepatitis C, Chronic List with clinical criteria and/or conditions Complete February 13, 2015 September 21, 2015 SR0417-000
Daxas Roflumilast Chronic obstructive pulmonary disease Do not list Complete November 30, 2010 July 27, 2011 SR0218-000
Delstrigo doravirine lamuvidine tenofovir disoproxil fumarate HIV-1 infection Reimburse with clinical criteria and/or conditions Complete November 16, 2018 May 14, 2019 SR0581-000
Denavir Penciclovir Herpes labialis (cold sores) Do not list Complete September 20, 2006 April 26, 2007 SR0075-000
Descovy Emtricitabine /tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete January 29, 2016 August 24, 2016 SR0470-000
Diacomit Stiripentol Dravet Syndrome List with criteria/condition Complete October 30, 2013 October 16, 2014 SR0360-000
Dificid Fidaxomicin Clostridium difficile infection Do not list at the submitted price Complete July 10, 2012 December 19, 2012 SR0285-000
Dovato dolutegravir / lamivudine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete February 21, 2019 September 30, 2019 SR0601-000
Duaklir Genuair Aclidinium bromide/formoterol fumarate dihydrate Chronic obstructive pulmonary disease List with clinical criteria and/or conditions Complete April 1, 2015 September 18, 2015 SR0423-000
Duobrii Halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete January 24, 2020 October 28, 2020 SR0638-000
Duodopa Levodopa / carbidopa (Drug Plan Submission) Parkinson's disease Reimburse with clinical criteria and/or conditions Complete February 8, 2018 August 22, 2018 SR0557-000
Duodopa Levodopa / carbidopa Parkinson's disease Do not list Complete December 19, 2008 July 22, 2009 SR0154-000
DuoTrav Travoprost and timolol maleate Glaucoma List with clinical criteria and/or conditions Complete March 24, 2006 August 24, 2006 SR0057-000
Dupixent dupilumab atopic dermatitis Do not reimburse Complete October 27, 2017 June 27, 2018 SR0533-000
Dupixent dupilumab atopic dermatitis Reimburse with clinical criteria and/or conditions Complete October 22, 2019 April 22, 2020 SR0636-000
Dupixent dupilumab Asthma Active November 26, 2020 SR0667-000
Dymista Azelastine HCl and fluticasone propionate Seasonal allergic rhinitis Do not list Complete December 9, 2014 June 17, 2015 SR0408-000
Dysport Therapeutic abobotulinumtoxinA lower limb spasticity Reimburse with clinical criteria and/or conditions Complete February 7, 2018 August 23, 2018 SR0556-000
Dysport Therapeutic abobotulinumtoxinA Upper limb spasticity Reimburse with clinical criteria and/or conditions Complete April 24, 2017 October 24, 2017 SR0517-000
Dysport Therapeutic abobotulinumtoxinA Cervical dystonia Reimburse with clinical criteria and/or conditions Complete January 31, 2017 July 26, 2017 SR0512-000
Ebixa Memantine hydrochloride Dementia (Alzheimer type), moderate to severe Do not list Complete December 21, 2004 November 23, 2005 SR0025-000
Edarbi Azilsartan medoxomil Hypertension Do not list at the submitted price Complete March 8, 2013 October 17, 2013 SR0317-000
Edarbyclor Azilsartan medoxomil + chlorthalidone Hypertension Do not list Complete March 8, 2013 October 17, 2013 SR0318-000
Edurant Rilpivirine HIV infection List Complete July 29, 2011 February 15, 2012 SR0243-000
Effient Prasugrel Acute coronary syndrome Do not list Complete December 12, 2011 June 14, 2012 SR0263-000
Effient Prasugrel hydrochloride Acute Coronary Syndrome Do not list Complete May 5, 2010 February 16, 2011 SR0200-000
Egrifta Tesamorelin Lipodystrophy, HIV-infected patients Do not reimburse Complete March 2, 2016 August 24, 2016 SR0477-000
Elaprase Idursulfase Mucopolysarccharidosis II (MPS II), Hunter Syndrome Do not list Complete July 13, 2007 December 19, 2007 SR0104-000
Elelyso Taliglucerase alfa Gaucher disease Do not list Complete August 15, 2014 October 28, 2015 SR0390-000
Eliquis Apixaban Thromboembolic events prevention, (atrial fibrillation) List with clinical criteria and/or conditions Complete September 25, 2012 March 20, 2013 SR0288-000
Eliquis Apixaban Venous thromboembolic events, prevention List with clinical criteria and/or conditions Complete December 20, 2011 June 14, 2012 SR0264-000
Eliquis Apixaban Venous thromboembolic events, treatment and prevention of recurrence List with clinical criteria and/or conditions Complete September 18, 2014 May 7, 2015 SR0397-000
Trelegy Ellipta fluticasone furoate umeclidinium vilanterol Chronic obstructive pulmonary disease (COPD) Reimburse with clinical criteria and/or conditions Complete March 1, 2018 August 23, 2018 SR0562-000
Incruse Ellipta Umeclidinium Chronic obstructive pulmonary disease List with criteria/condition Complete March 4, 2015 September 18, 2015 SR0422-000
Emend Aprepitant Nausea and Vomiting, Chemotherapy induced List with clinical criteria and/or conditions Complete August 29, 2007 February 20, 2008 SR0109-000
Restasis ophthalmic emulsion Cyclosporine Dry eye disease Do not list Complete December 17, 2010 July 18, 2011 SR0222-000
Enablex Darifenacin hydrobromide Bladder, overactive List with clinical criteria and/or conditions Complete October 1, 2008 April 16, 2009 SR0147-000
Enablex Darifenacin hydrobromide Bladder, overactive Do not list Complete April 26, 2006 October 19, 2006 SR0061-000
Enspryng satralizumab Neuromyelitis optica spectrum disorder Active October 22, 2020 SR0663-000
Entresto Sacubitril/valsartan Heart failure, NYHA class II or III List with clinical criteria and/or conditions Complete September 18, 2015 March 18, 2016 SR0447-000
Entresto sacubitril/valsartan Heart failure, NYHA Class II or III Active May 22, 2020 SR0644-000
Entuzity KwikPen human insulin Diabetes mellitus Active January 27, 2021 SR0672-000
Entyvio vedolizumab Crohn’s disease Active July 23, 2020 January 21, 2021 SR0647-000
Entyvio Vedolizumab Ulcerative colitis List with clinical criteria and/or conditions Complete February 20, 2015 October 28, 2015 SR0421-000
Entyvio Vedolizumab Crohn's disease Reimburse with clinical criteria and/or conditions Complete April 27, 2016 October 31, 2016 SR0487-000
Entyvio vedolizumab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete November 21, 2019 May 19, 2020 SR0635-000
Epclusa Sofosbuvir/ velpatasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete April 22, 2016 October 26, 2016 SR0486-000
Erelzi Etanercept Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete February 2, 2017 July 25, 2017 SE0513-000
Esbriet Pirfenidone Idiopathic pulmonary fibrosis Do not list Complete October 5, 2012 April 18, 2013 SR0292-000
Esbriet Pirfenidone Idiopathic pulmonary fibrosis List with criteria/condition Complete August 29, 2014 April 15, 2015 SR0393-000
Eucrisa crisaborole atopic dermatitis Do not reimburse Complete May 25, 2018 March 27, 2019 SR0570-000
Evenity romosozumab Osteoporosis, postmenopausal women Active February 1, 2021 SR0676-000
Evra Norgelestromin/ethinyl estradiol Contraceptive, patch Do not list Complete December 19, 2003 June 23, 2004 SR0004-000
Exelon Patch Rivastigmine Dementia (Alzheimer's type) Do not list Complete December 21, 2007 July 23, 2008 SR0123-000
Exjade Deferasirox Iron overload List with clinical criteria and/or conditions Complete October 26, 2006 April 19, 2007 SR0081-000
Eylea Aflibercept Macular edema, diabetic List with clinical criteria and/or conditions Complete September 16, 2014 May 7, 2015 SR0396-000
Eylea Aflibercept Macular edema, central retinal vein occlusion List with clinical criteria and/or conditions Complete October 17, 2014 May 7, 2015 SR0401-000
Eylea Aflibercept Macular degeneration, age-related List with criteria/condition Complete November 18, 2013 October 20, 2014 SR0361-000
Eylea Aflibercept Macular edema, branch retinal vein occlusion Reimburse with clinical criteria and/or conditions Complete December 14, 2015 July 27, 2016 SR0460-000
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete February 24, 2004 November 24, 2004 SR0007-000
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete December 10, 2004 May 18, 2005 SR0028-000
Fampyra Fampridine Multiple sclerosis, improve walking disability Do not list Complete April 16, 2012 November 28, 2012 SR0275-000
Fampyra Fampridine Multiple sclerosis, improve walking disability Withdrawn November 6, 2014 SR0404-000
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete October 24, 2018 March 27, 2019 SF0592-000
Fasenra benralizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete February 23, 2018 August 21, 2018 SR0561-000
Fentora Fentanyl buccal Pain (breakthrough), cancer (adults) Do not reimburse Complete July 12, 2016 February 21, 2017 SR0494-000
Ferriprox Deferiprone Transfusional iron overload List with clinical criteria and/or conditions Complete September 24, 2015 March 18, 2016 SR0448-000
Fibristal ulipristal acetate Uterine fibroids (signs and symptoms) Reimburse with clinical criteria and/or conditions Complete March 28, 2019 July 24, 2019 SF0609-000
Fibristal ulipristal acetate Uterine fibroids (signs and symptoms) Reimburse with clinical criteria and/or conditions Complete June 21, 2017 November 22, 2017 SF0528-000
Fibristal Ulipristal acetate Uterine fibroids List with criteria/condition Complete April 17, 2013 November 15, 2013 SR0326-000
Finacea Azelaic acid Rosacea List Complete August 31, 2010 February 16, 2011 SR0209-000
Firazyr Icatibant Hereditary angioedema List with clinical criteria and/or conditions Complete March 4, 2014 December 19, 2014 SR0375-000
Firazyr icatibant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Forteo Teriparatide (rDNA origin) injection Osteoporosis (in women), Severe Do not list Complete October 23, 2009 March 17, 2010 SR0180-000
Forteo Teriparatide (rDNA origin) injection Osteoporosis, glucocorticoid induced Do not list Complete December 18, 2008 July 22, 2009 SR0152-000
Forteo Teriparatide (rDNA origin) injection Osteoporosis Do not list Complete June 8, 2004 December 22, 2004 SR0015-000
Forteo Teriparatide (rDNA origin) injection Osteoporosis Withdrawn May 29, 2006 SR0065-000
Forteo Teriparatide (rDNA origin) injection Osteoporosis Withdrawn June 12, 2009 SR0169-000
Forteo Teriparatide (rDNA origin) injection Osteoporosis Withdrawn December 18, 2008 SR0157-000
Forxiga Dapagliflozin Diabetes mellitus, type 2 Do not list Complete September 4, 2015 April 27, 2016 SR0445-000
Forxiga dapagliflozin Heart failure with reduced ejection fraction Reimburse with clinical criteria and/or conditions Active March 31, 2020 December 23, 2020 SR0642-000
Forxiga Dapagliflozin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete April 30, 2015 November 20, 2015 SR0428-000
Fosavance Alendronate sodium/cholecalciferol Osteoporosis Do not list Complete March 27, 2006 September 27, 2006 SR0059-000
Fosrenol Lanthanum carbonate hydrate Hyperphosphatemia, end-stage renal disease Do not list Complete June 28, 2007 January 30, 2008 SR0100-000
Fulphila pegfilgrastim Febrile neutropenia in non-myeloid malignancies Complete November 14, 2018 SE0588-000
Fycompa Perampanel Epilepsy, partial onset seizures List with criteria/condition Complete March 8, 2013 October 17, 2013 SR0316-000
Fycompa Perampanel Epilepsy, primary generalized tonic-clonic seizures Reimburse with clinical criteria and/or conditions Complete November 24, 2015 May 18, 2016 SR0458-000
Galafold migalastat Fabry Disease Reimburse with clinical criteria and/or conditions Complete June 9, 2017 January 24, 2018 SR0522-000
Galexos Simeprevir Hepatitis C, chronic List with criteria/condition Complete August 22, 2013 June 18, 2014 SR0347-000
Gelnique Oxybutynin Chloride Gel Overactive bladder Do not list Complete October 25, 2011 May 24, 2012 SR0260-000
Genotropin Somatropin Growth hormone deficiency, adult List with criteria/condition Complete May 27, 2013 December 20, 2013 SR0332-000
Genotropin Somatropin Growth hormone deficiency, children List with criteria/condition Complete May 27, 2013 December 20, 2013 SR0333-000
Genotropin Somatropin Turner Syndrome List with criteria/condition Complete May 27, 2013 December 20, 2013 SR0334-000
Tudorza Genuair Aclidinium bromide Chronic Obstructive Pulmonary Disease List with criteria/condition Complete August 21, 2013 April 21, 2014 SR0346-000
Genvoya Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide HIV infection List Complete September 24, 2015 March 18, 2016 SR0449-000
Gilenya Fingolimod Multiple Sclerosis, relapsing-remitting List with clinical criteria and/or conditions Complete May 10, 2011 November 16, 2011 SR0228-000
Givlaari givosiran Acute hepatic porphyria (AHP) in adults Received February 23, 2021 SR0679-000
Glatect Glatiramer acetate Relapsing Remitting Multiple Sclerosis (RRMS) Reimburse with clinical criteria and/or conditions Complete January 20, 2017 July 25, 2017 SE0510-000
Grastek Phleum pratense Allergic rhinitis Do not list Complete September 30, 2013 September 24, 2014 SR0352-000
Grastofil Filgrastim Neutropenia List with clinical criteria and/or conditions Complete September 11, 2015 March 18, 2016 SE0446-000
Harvoni Ledipasvir / Sofosbuvir Hepatitis C, chronic List with criteria/condition Complete September 15, 2014 March 18, 2015 SR0395-000
Harvoni ledipasvir, sofosbuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 18, 2016 SF0465-000
Hemangiol Propranolol oral solution Infantile hemangioma Reimburse with clinical criteria and/or conditions Complete August 25, 2016 February 21, 2017 SR0496-000
Hemangiol Propranolol Infantile hemangioma Withdrawn December 23, 2014 SR0411-000
Hemlibra emicizumab Bleeding prevention, hemophilia A Reimburse with clinical criteria and/or conditions Complete June 30, 2020 December 21, 2020 ST0651-000
Hepsera Adefovir dipivoxil Hepatitis B List with clinical criteria and/or conditions Complete June 29, 2007 October 18, 2007 SF0103-000
Hepsera Adefovir dipivoxil Hepatitis B Do not list Complete April 24, 2006 November 29, 2006 SR0060-000
Holkira Pak ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 19, 2016 SF0466-000
Holkira Pak Ombitasvir/paritaprevir/ritonavir and dasabuvir Hepatitis C, chronic List with clinical criteria and/or conditions Complete December 3, 2014 June 18, 2015 SR0406-000
Humira Adalimumab Crohn's disease List with clinical criteria and/or conditions Complete July 12, 2007 December 19, 2007 SR0105-000
Humira Adalimumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete September 24, 2004 February 11, 2005 SR0022-000
Humira Adalimumab Arthritis, juvenile idiopathic List with clinical criteria and/or conditions Complete February 4, 2013 July 18, 2013 SR0308-000
Humira Adalimumab Ankylosing spondylitis (AS) List with clinical criteria and/or conditions Complete November 17, 2006 June 27, 2007 SR0087-000
Humira Adalimumab Ulcerative colitis Do not list at the submitted price Complete September 25, 2015 April 15, 2016 SR0450-000
Humira Adalimumab ulcerative colitis Withdrawn December 23, 2013 SR0365-000
Humira Adalimumab Psoriasis List with clinical criteria and/or conditions Complete April 15, 2008 October 16, 2008 SR0130-000
Humira Adalimumab Arthritis, Psoriatic List with clinical criteria and/or conditions Complete June 21, 2006 November 29, 2006 SR0066-000
Humira Adalimumab Hidradenitis suppurativa Reimburse with clinical criteria and/or conditions Complete November 3, 2015 May 19, 2016 SR0455-000
Simponi I.V. Golimumab Arthritis, rheumatoid List with criteria/condition Complete September 12, 2013 July 17, 2014 SR0351-000
Stelara/Stelara I.V ustekinumab Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete August 12, 2019 July 16, 2020 SR0627-000
Stelara/Stelara I.V. ustekinumab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete September 12, 2016 March 21, 2017 SR0501-000
Ikervis cyclosporine keratitis, severe Withdrawn May 15, 2017 SR0518-000
Ilaris Canakinumab Cryopyrin-Associated Periodic Syndrome Do not list Complete July 7, 2010 January 26, 2011 SR0204-000
Ilaris Canakinumab Systemic Juvenile Idiopathic Arthritis Reimburse with clinical criteria and/or conditions Complete December 23, 2015 June 17, 2016 SR0463-000
Ilumya tildrakizumab Psoriasis, moderate to severe plaque Active July 15, 2019 SR0624-000
Iluvien fluocinolone acetonide Diabetic macular edema (DME) Withdrawn December 21, 2017 SR0549-000
Iluvien fluocinolone acetonide intravitreal implant diabetic macular edema Do not reimburse Complete April 3, 2019 September 26, 2019 SR0608-000
Imbruvica ibrutinib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Imfinzi durvalumab Extensive-stage small cell lung cancer Active December 1, 2020 PC0234-000
Incivek Telaprevir Hepatitis C, chronic List with clinical criteria and/or conditions Complete August 23, 2011 February 15, 2012 SR0249-000
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete February 19, 2013 June 13, 2013 SF0311-000
Incivek Telaprevir Hepatitis C, chronic List with criteria/condition Complete December 21, 2012 June 13, 2013 SF0305-000
Inflectra Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis List with criteria/condition Complete June 17, 2014 December 19, 2014 SE0384-000
Inrebic fedratinib Myelofibrosis Active November 5, 2020 PC0205-000
Inspiolto Respimat Tiotropium / olodaterol List with criteria/condition Complete June 4, 2015 December 17, 2015 SR0436-000
Inspra Eplerenone Heart failure, NYHA class II Do not list at the submitted price Complete July 12, 2013 April 24, 2014 SR0342-000
Inspra Eplerenone Post myocardial infarction Do not list Complete May 6, 2009 November 25, 2009 SR0165-000
Intelence Etravirine HIV List with clinical criteria and/or conditions Complete April 2, 2008 August 14, 2008 SR0129-000
Intuniv XR Guanfacine hydrochloride Attention-deficit/hyperactivity disorder (ADHD) Do not list Complete August 27, 2013 September 24, 2014 SR0349-000
Invega Paliperidone Schizophrenia Do not list Complete November 1, 2007 May 28, 2008 SR0112-000
Invega Sustenna Paliperidone palmitate Schizophrenia Do not list Complete July 9, 2010 April 25, 2011 SR0206-000
Invokamet Canagliflozin and metformin hydrochloride diabetes mellitus, type 2 Reimburse with clinical criteria and/or conditions Complete March 3, 2016 August 25, 2016 SR0480-000
Invokana Canagliflozin Diabetes Mellitus, Type 2 Withdrawn June 5, 2013 SR0335-000
Invokana Canagliflozin Diabetes mellitus, type 2 List with criteria/condition Complete February 24, 2014 January 15, 2015 SR0370-000
Iressa Gefitinib Cancer, Lung , non-small cell Do not list Complete December 22, 2003 June 23, 2004 SR0003-000
Isentress Raltegravir HIV List with clinical criteria and/or conditions Complete November 29, 2007 May 14, 2008 SR0115-000
Isentress Raltegravir HIV (treatment naïve) Do not list Complete December 4, 2009 June 23, 2010 SR0191-000
Izba travoprost ophthalmic solution Glaucoma and ocular hypertension Reimburse with clinical criteria and/or conditions Complete March 1, 2017 October 25, 2017 SR0516-000
Janumet Sitagliptin phosphate monohydrate / metformin hydrochloride Diabetes mellitus (Type 2) List with clinical criteria and/or conditions Complete November 4, 2009 June 23, 2010 SR0182-000
Januvia Sitagliptin phosphate Diabetes mellitus (Type 2) Do not list Complete December 20, 2007 June 18, 2008 SR0122-000
Januvia Sitagliptin phosphate Diabetes mellitus (Type 2) List with clinical criteria and/or conditions Complete October 29, 2009 June 23, 2010 SR0181-000
Jardiance Empagliflozin Diabetes mellitus, type 2 with high cardiovascular risk Reimburse with clinical criteria and/or conditions Complete April 27, 2016 October 26, 2016 SR0488-000
Jardiance Empagliflozin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete April 23, 2015 October 15, 2015 SR0427-000
Jentadueto Linagliptin-metformin Diabetes mellitus, type 2 List with criteria/condition Complete March 8, 2013 October 17, 2013 SR0306-000
Jetrea Ocriplasmin Vitreomacular adhesion List with criteria/condition Complete June 6, 2013 December 20, 2013 SR0337-000
Jinarc Tolvaptan Autosomal dominant polycystic kidney disease Do not list Complete May 29, 2015 February 24, 2016 SR0435-000
Jorveza budesonide Eosinophilic esophagitis, adults Reimburse with clinical criteria and/or conditions Complete November 8, 2019 October 28, 2020 SR0634-000
Jorveza budesonide Maintenance of Eosinophilic esophagitis in adults Active November 5, 2020 SR0666-000
Jublia efinaconazole Onychomycosis Do not reimburse Complete August 2, 2018 May 23, 2019 SR0577-000
Juluca Dolutegravir rilpivirine HIV infection Reimburse with clinical criteria and/or conditions Complete December 21, 2017 June 20, 2018 SR0551-000
Jurnista Hydromorphone hydrochloride Pain, Chronic (moderate to severe) Do not list Complete December 4, 2009 May 19, 2010 SR0190-000
Juxtapid Lomitapide Hypercholesterolemia, homozygous familial Do not list Complete July 8, 2014 April 17, 2015 SR0386-000
Kalydeco Ivacaftor Cystic Fibrosis, CFTR gating mutations List with criteria/condition Complete May 1, 2014 December 19, 2014 SR0379-000
Kalydeco Ivacaftor Cystic fibrosis, R117H CFTR gating mutation List with criteria/condition Complete May 8, 2015 November 19, 2015 SR0430-000
Kalydeco Ivacaftor Cystic fibrosis, G551D mutation List with criteria/condition Complete September 27, 2012 March 22, 2013 SR0291-000
Kanuma sebelipase alfa Lysosomal acid lipase deficiency Reimburse with clinical criteria and/or conditions Complete November 2, 2017 September 26, 2018 SR0544-000
Kazano Alogliptin plus metformin Diabetes mellitus, type 2 Do not list Complete January 30, 2014 January 15, 2015 SR0367-000
Kesimpta ofatumumab Multiple Sclerosis, relapsing Active August 25, 2020 SR0657-000
Kevzara sarilumab Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete October 12, 2016 April 18, 2017 SR0503-000
Keytruda pembrolizumab Colorectal cancer Active November 30, 2020 PC0235-000
Keytruda pembrolizumab Classical Hodgkin lymphoma Received January 29, 2021 PC0236-000
Kineret anakinra Still's disease Active December 21, 2020 SR0662-000
Kivexa Abacavir/lamivudine HIV infection List in a similar manner to other drugs in class Complete July 26, 2005 December 7, 2005 SR0038-000
Komboglyze Saxagliptin + metformin Diabetes Mellitus, Type 2 Withdrawn June 6, 2013 SR0336-000
Komboglyze Saxagliptin + metformin Diabetes Mellitus, type 2 List with criteria/condition Complete August 23, 2013 June 20, 2014 SR0348-000
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Reimburse with clinical criteria and/or conditions Complete February 1, 2016 October 26, 2016 SR0472-000
Kuvan Sapropterin dihydrochloride Phenylketonuria (PKU) Do not list Complete July 8, 2010 January 26, 2011 SR0205-000
Kuvan Sapropterin dihydrochloride Phenylketonuria Complete June 1, 2011 SF0236-000
Kynmobi apomorphine hydrochloride Parkinson’s disease Reimburse with clinical criteria and/or conditions Active June 25, 2020 February 24, 2021 SR0650-000
Kynmobi apomorphine hydrochloride Parkinson’s Disease Withdrawn February 25, 2019 SR0604-000
Lancora Ivabradine Heart failure, NYHA class II or III Reimburse with clinical criteria and/or conditions Complete November 8, 2016 May 24, 2017 SR0506-000
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Complete June 9, 2009 SF0166-000
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Do not list Complete February 11, 2005 September 28, 2005 SR0033-000
Lantus Insulin glargine (rDNA origin) Diabetes mellitus, Type 1 & 2 Do not list Complete March 27, 2006 October 25, 2006 SR0058-000
Lapelga Pegfilgrastim Febrile neutropenia Complete February 23, 2018 SE0555-000
Latuda Lurasidone Schizophrenia Do not list Complete July 3, 2012 January 23, 2013 SR0284-000
Latuda Lurasidone Schizophrenia List with criteria/condition Complete May 9, 2013 December 20, 2013 SR0331-000
Latuda lurasidone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Ledaga chlormethine hydrochloride T-cell lymphoma Active December 21, 2020 PC0242-000
Lemtrada Alemtuzumab Multiple sclerosis, relapsing-remitting List with criteria/condition Complete November 27, 2014 June 18, 2015 SR0405-000
Lemtrada Alemtuzumab Multiple sclerosis, relapsing-remitting Withdrawn October 1, 2013 SR0355-000
Levemir Insulin detemir Diabetes mellitus Do not list Complete December 19, 2005 August 2, 2006 SR0049-000
Levemir Insulin detemir Diabetes mellitus Do not list Complete March 10, 2009 August 20, 2009 SR0160-000
Levemir Insulin detemir Diabetes mellitus Withdrawn February 2, 2009 SR0158-000
Levemir Insulin detemir Diabetes mellitus Type1, Pediatrics Do not list Complete March 10, 2009 August 20, 2009 SR0172-000
pdp-levETIRAcetam Levetiracetam Epilepsy Reimburse with clinical criteria and/or conditions Active July 17, 2020 February 3, 2021 SR0653-000
Lixiana VTE Edoxaban Venous thromboembolism, treatment and recurrence prevention. Reimburse with clinical criteria and/or conditions Complete September 9, 2016 May 25, 2017 SR0499-000
Lixiana NVAF Edoxaban Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. Reimburse with clinical criteria and/or conditions Complete September 9, 2016 March 21, 2017 SR0500-000
Lodalis Colesevelam hydrochloride Hypercholesterolemia Do not list at the submitted price Complete April 27, 2012 December 19, 2012 SR0274-000
Lokelma sodium zirconium cyclosilicate Hyperkalemia, adults Do not reimburse Complete May 17, 2019 March 25, 2020 SR0612-000
Lotemax Loteprednol etabonate Post-operative inflammation following cataract surgery Do not list Complete December 2, 2009 May 19, 2010 SR0186-000
Lucentis Ranibizumab injection Macular edema, secondary to retinal vein occlusion List with clinical criteria and/or conditions Complete April 25, 2012 October 18, 2012 SR0276-000
Lucentis Ranibizumab Macular degeneration, age-related List with clinical criteria and/or conditions Complete July 12, 2007 March 27, 2008 SR0098-000
Lucentis Ranibizumab Myopic choroidal neovascularisation List with criteria/condition Complete February 28, 2014 February 19, 2015 SR0373-000
Lucentis Ranibizumab Macular edema, diabetic List with clinical criteria and/or conditions Complete September 14, 2011 March 19, 2012 SR0253-000
Luxturna voretigene neparvovec Vision loss, inherited retinal dystrophy Reimburse with clinical criteria and/or conditions Complete April 23, 2020 November 12, 2020 SG0643-000
Lyrica Pregabalin diabetic peripheral neuropathy Do not list Complete March 20, 2009 September 23, 2009 SR0162-000
Lyrica Pregabalin Pain, Neuropathic Do not list Complete June 27, 2005 January 25, 2006 SR0036-000
Pantoloc M Pantoprazole magnesium Gastric acid secretion, reduction of List in a similar manner to other drugs in class Complete March 17, 2006 July 20, 2006 SR0054-000
Macugen Pegaptanib sodium Macular degeneration, age-related Do not list Complete October 20, 2005 May 25, 2006 SR0044-000
Mavenclad cladribine Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete December 1, 2017 October 24, 2018 SR0546-000
Maviret glecaprevir pibrentasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete June 9, 2017 January 23, 2018 SR0523-000
Mayzent siponimod Secondary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete September 26, 2019 July 21, 2020 SR0631-000
MDK-Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete September 29, 2017 April 25, 2018 SR0538-000
Mictoryl Propiverine hydrochloride Overactive bladder (OAB) Reimburse with clinical criteria and/or conditions Complete October 14, 2016 April 19, 2017 SR0504-000
Mifegymiso Mifepristone and misoprostol Medical termination of pregnancy (gestational age up to 49 days) Withdrawn February 12, 2016 SR0473 -000
Mifegymiso Mifepristone and misoprostol Medical termination of pregnancy (gestational age up to 49 days) Reimburse Complete October 7, 2016 April 18, 2017 SR0502-000
Monoferric Iron (III) Isomaltoside 1000 iron deficiency anemia Reimburse with clinical criteria and/or conditions Complete June 26, 2019 March 25, 2020 SR0622-000
Monoprost latanoprost glaucoma and ocular hypertension Reimburse with clinical criteria and/or conditions Complete October 25, 2017 April 24, 2018 SR0541-000
Movapo apomorphine hydrochloride Parkinson's disease Reimburse with clinical criteria and/or conditions Complete July 6, 2017 January 23, 2018 SR0527-000
Mozobil Plerixafor Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma Do not list Complete January 24, 2012 September 26, 2012 SR0265-000
Multaq Dronedarone hydrochloride Atrial fibrillation Do not list Complete September 18, 2009 May 27, 2010 SR0177-000
Myfortic Mycophenolate sodium Organ rejection in allogeneic renal transplants, Prophylaxis List in a similar manner to other drugs in class Complete March 3, 2005 July 8, 2005 SR0034-000
Myozyme Alglucosidase Pompe's disease List with clinical criteria and/or conditions Complete October 10, 2006 June 14, 2007 SR0080-000
Myrbetriq Mirabegron Overactive bladder List with criteria/condition Complete November 27, 2013 November 12, 2014 SR0363-000
Myrbetriq Mirabegron Overactive bladder Withdrawn March 8, 2013 SR0319-000
Naglazyme Galsulfase (Drug Plan Submission) Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) List with clinical criteria and/or conditions Complete August 20, 2015 February 19, 2016 SR0434-000
Nesina Alogliptin Diabetes mellitus, type 2 Do not list Complete January 30, 2014 January 15, 2015 SR0368-000
Neulasta Pegfilgrastim Neutropenia List with clinical criteria and/or conditions Complete March 29, 2004 October 27, 2004 SR0009-000
Neupro Rotigotine Parkinson's disease Do not list Complete July 31, 2013 May 28, 2014 SR0344-000
Neupro Rotigotine Parkinson’s disease List with clinical criteria and/or conditions Complete May 21, 2015 November 19, 2015 SR0432-000
Nexavar Sorafenib tablets Cancer, Renal cell carcinoma Do not list Complete July 31, 2006 February 28, 2007 SR0071-000
Nexplanon etonogestrel Prevention of pregnancy Reimburse with clinical criteria and/or conditions Complete June 3, 2020 October 20, 2020 SR0648-000
Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete January 25, 2018 August 23, 2018 SR0554-000
Norprolac Quinagolide hydrochloride Hyperprolactinemia List with clinical criteria and/or conditions Complete November 23, 2005 May 17, 2006 SR0046-000
Norprolac Quinagolide hydrochloride Hyperprolactinemia Do not list Complete December 16, 2004 September 28, 2005 SR0026-000
Nplate Romiplostim Chronic immune (idiopathic) thrombocytopenic purpura (ITP) Do not list Complete September 29, 2009 May 27, 2010 SR0179-000
Nucala mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete October 24, 2018 March 27, 2019 SF0593-000
Nucala Mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete December 18, 2015 June 16, 2016 SR0461-000
Nucynta tapentadol hydrochloride pain, severe Do not reimburse Complete April 17, 2018 October 23, 2018 SR0563-000
NuvaRing Etonogestrel/ethinyl estradiol Contraceptive, ring List with clinical criteria and/or conditions Complete May 5, 2006 November 29, 2006 SR0062-000
Ocaliva Obeticholic Acid Primary Biliary Cholangitis Reimburse with clinical criteria and/or conditions Complete December 22, 2016 July 25, 2017 SR0509-000
Ocrevus ocrelizumab multiple sclerosis, relapsing Reimburse with clinical criteria and/or conditions Complete May 16, 2017 November 21, 2017 SR0519-000
Ocrevus ocrelizumab Primary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete October 26, 2017 April 26, 2018 SR0542-000
Odefsey emtricitabine/rilpivirine/ tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete November 24, 2016 May 25, 2017 SR0507-000
Ofev nintedanib chronic fibrosing interstitial lung diseases Reimburse with clinical criteria and/or conditions Active July 24, 2020 February 24, 2021 SR0654-000
Ofev Nintedanib Idiopathic pulmonary fibrosis List with clinical criteria and/or conditions Complete April 23, 2015 October 15, 2015 SR0426-000
Olmetec Olmesartan medoxomil Hypertension List in a similar manner to other drugs in class Complete November 28, 2008 May 27, 2009 SR0150-000
Olmetec Plus Olmesartan medoxomil + hydrochlorothiazide Hypertension List in a similar manner to other drugs in class Complete November 28, 2008 May 27, 2009 SR0151-000
Olumiant baricitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete December 20, 2018 August 2, 2019 SR0597-000
Omnaris Ciclesonide nasal spray Allergic Rhinitis (seasonal and perennial) Do not list Complete May 7, 2008 November 12, 2008 SR0137-000
Omnitrope Somatropin (rDNA origin) Growth hormone deficiency in children and adults Complete June 12, 2009 SR0167-000
Onbrez Indacaterol Chronic obstructive pulmonary disease List in a similar manner Complete February 29, 2012 August 16, 2012 SR0273-000
Onglyza Saxagliptin Diabetes mellitus, type 2 List with criteria/condition Complete May 9, 2013 November 15, 2013 SR0329-000
Onglyza Saxagliptin Diabetes mellitus (Type 2) Do not list Complete November 9, 2009 June 17, 2010 SR0185-000
Onglyza Saxagliptin Diabetes mellitus, type 2 Withdrawn May 28, 2012 SR0280-000
Onpattro patisiran Polyneuropathy in hereditary transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete January 25, 2019 July 25, 2019 SR0598-000
Onsolis Fentanyl Citrate Pain, breakthrough cancer pain Withdrawn May 10, 2011 SR0229-000
Onsolis Fentanyl Citrate Pain, breakthrough cancer pain Do not list Complete August 22, 2011 February 15, 2012 SR0248-000
Onstryv safinamide Parkinson's disease Do not reimburse Complete May 29, 2019 March 25, 2020 SR0617-000
Onureg azacitidine Acute myeloid leukemia Pending PC0245-000
Opdivo-Yervoy nivolumab-ipilimumab Malignant Pleural Mesothelioma (MPM) Active October 29, 2020 PC0229-000
Opsumit Macitentan Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete December 18, 2015 January 28, 2015 SR0364-000
Oralair Grass Pollen Allergen Extract Allergic rhinitis List with criteria/condition Complete September 21, 2012 March 20, 2013 SR0290-000
Orencia Abatacept Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete October 26, 2006 June 27, 2007 SR0084-000
Orencia Abatacept Arthritis, rheumatoid List with clinical criteria and/or conditions Complete November 29, 2012 July 18, 2013 SR0299-000
Orencia Abatacept Arthritis, Rheumatoid List in a similar manner Complete December 2, 2009 June 17, 2010 SR0187-000
Orencia Abatacept Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid List with clinical criteria and/or conditions Complete August 29, 2008 April 22, 2009 SR0145-000
Orfadin nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete August 29, 2017 February 21, 2018 SR0531-000
Orilissa elagolix CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation Do not reimburse Complete January 28, 2016 October 26, 2016 SR0471-000
Orkambi lumacaftor/ivacaftor Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older Do not reimburse Complete February 22, 2018 September 26, 2018 SR0559-000
Otezla Apremilast Plaque psoriasis Do not list Complete October 8, 2014 July 22, 2015 SR0400-000
Otezla Apremilast Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete March 3, 2016 October 26, 2016 SR0478-000
Otezla Apremilast Arthritis, psoriatic List with criteria/condition Complete June 8, 2015 December 17, 2015 SR0437-000
Ozanex ozenoxacin Impetigo Do not reimburse Complete January 25, 2018 October 24, 2018 SR0553-000
Ozempic semaglutide Diabetes mellitus, type 2 Reimburse with clinical criteria and/or conditions Complete November 23, 2018 May 15, 2019 SR0594-000
Ozurdex dexamethasone Diabetic macular edema Do not reimburse Complete September 26, 2017 October 24, 2018 SR0535-000
Ozurdex Dexamethasone intravitreal implant Macular edema, central retinal vein occlusion Do not list Complete September 1, 2011 April 25, 2012 SR0247-000
Pegasys RBV Peginterferon alfa-2a and Ribavirin Hepatitis C, chronic List in a similar manner to other drugs in class Complete May 14, 2004 October 14, 2004 SR0013-000
Perseris risperidone Schizophrenia, adults Active January 29, 2021 SR0671-000
Pheburane Sodium phenylbutyrate Urea cycle disorders List Complete October 20, 2015 April 15, 2016 SR0452-000
Picato Ingenol mebutate Actinic keratosis Do not list Complete May 9, 2013 January 22, 2014 SR0330-000
Picato Ingenol mebutate Actinic keratosis Complete May 26, 2014 SF0382-000
Pifeltro doravirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete November 16, 2018 May 14, 2019 SR0582-000
Plegridy Peginterferon beta-1a Multiple sclerosis, relapsing-remitting List with criteria/condition Complete June 26, 2015 December 17, 2015 SR0440-000
Teveten Plus Eprosartan mesylate/ hydrochlorothiazide Hypertension, Essential List in a similar manner to other drugs in class Complete July 8, 2004 December 15, 2004 SR0016-000
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete March 18, 2013 July 18, 2013 SF0320-000
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete October 28, 2010 June 22, 2011 SR0214-000
Pradaxa Dabigatran etexilate Thromboembolism (venous), prevention Do not list Complete July 8, 2008 January 28, 2009 SR0140-000
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled May 31, 2010 SR0202-000
Praluent Alirocumab Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete January 12, 2016 July 20, 2016 SR0469-000
Praxbind Idarucizumab (Drug Plan Submission) Reversal of dabigatran anticoagulant effects Withdrawn May 30, 2016 SR0492-000
Prevymis letermovir Cytomegalovirus infection, prophylaxis Reimburse with clinical criteria and/or conditions Complete December 7, 2017 June 20, 2018 SR0545-000
Prexige Lumiracoxib Osteoarthritis (Knee) Do not list Complete December 15, 2006 July 25, 2007 SR0090-000
Prezcobix Darunavir/cobicistat HIV Infection List with criteria/condition Complete May 22, 2014 March 18, 2015 SR0381-000
Prezista Darunavir HIV infection List with clinical criteria and/or conditions Complete August 29, 2006 February 14, 2007 SR0072-000
Prezista Darunavir HIV (treatment naive) List with clinical criteria and/or conditions Complete March 27, 2009 October 14, 2009 SR0163-000
Prezista Darunavir HIV infection (Pediatric) List with clinical criteria and/or conditions Complete December 22, 2009 June 17, 2010 SR0194-000
Pristiq Desvenlafaxine succinate Depressive, Major Disorder (MDD) Do not list Complete March 5, 2009 September 23, 2009 SR0159-000
Probuphine buprenorphine hydrochloride Opioid drug dependence, treatment Reimburse with clinical criteria and/or conditions Complete December 21, 2017 August 22, 2018 SR0550-000
Procysbi cysteamine bitartrate Nephropathic cystinosis Reimburse with clinical criteria and/or conditions Complete August 8, 2017 January 24, 2018 SR0526-000
Prolia Denosumab Osteoporosis, postmenopausal women List with clinical criteria and/or conditions Complete August 26, 2010 March 30, 2011 SR0208-000
Prolia Denosumab Osteoporosis Reimburse with clinical criteria and/or conditions Complete October 26, 2015 May 20, 2016 SF0453-000
Prolia Denosumab (Drug Plan Submission) Osteoporosis, men List with clinical criteria and/or conditions Complete March 10, 2015 September 21, 2015 SR0414-000
Quinsair Levofloxacin Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections Reimburse with clinical criteria and/or conditions Complete May 31, 2016 November 21, 2016 SR0493-000
Radicava edaravone amyotrophic lateral sclerosis Reimburse with clinical criteria and/or conditions Complete July 5, 2018 March 27, 2019 SR0573-000
Ralivia Tramadol hydrochloride Pain Do not list Complete October 29, 2007 June 25, 2008 SR0110-000
RAPAFLO Silodosin Benign prostatic hyperplasia Do not list Complete October 25, 2011 April 19, 2012 SR0261-000
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque List with clinical criteria and/or conditions Complete October 25, 2005 August 24, 2006 SR0043-000
Raptiva Efalizumab Psoriasis, moderate to severe chronic plaque Complete June 19, 2007 SF0102-000
Rasilez Aliskiren Hypertension Do not list Complete November 30, 2007 June 25, 2008 SR0118-000
Ravicti glycerol phenylbutyrate Urea cycle disorders Reimburse with clinical criteria and/or conditions Complete August 30, 2016 March 21, 2017 SR0497-000
Rebif Interferon beta-1a Clinically isolated syndrome Do not list Complete March 8, 2013 August 15, 2013 SR0298-000
Reblozyl luspatercept Myelodysplastic syndromes-associated anemia Received January 28, 2021 SR0670-000
Reblozyl luspatercept beta-thalassemia associated anemia Active November 26, 2020 SR0669-000
Relistor Methylnaltrexone bromide Constipation, Opioid-induced Do not list Complete May 7, 2008 January 28, 2009 SR0135-000
Relpax Eletriptan hydrobromide Migraine Do not list Complete September 21, 2004 March 23, 2005 SR0021-000
Remicade Infliximab Ulcerative Colitis Do not list Complete September 29, 2008 April 22, 2009 SR0146-000
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) List with clinical criteria and/or conditions Complete February 24, 2006 July 20, 2006 SR0052-000
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) Do not list Complete July 14, 2004 November 17, 2004 SR0011-000
Remsima Infliximab Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis Withdrawn May 30, 2014 SE0383-000
Remsima infliximab Rheumatoid arthritis Active September 24, 2020 SR0659-000
Renflexis infliximab rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Reimburse with clinical criteria and/or conditions Complete September 5, 2017 February 20, 2018 SE0532-000
Repatha Evolocumab Primary hyperlipidemia; mixed dyslipidemia List with clinical criteria and/or conditions Complete June 30, 2015 February 19, 2016 SR0441-000
Repatha Evolocumab Primary hyperlipidemia and mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete February 17, 2017 November 22, 2017 SR0515-000
Replagal Agalsidase alfa Fabry Disease Do not list Complete February 19, 2004 November 24, 2004 SR0006-000
Resotran Prucalopride Constipation, chronic Do not list Complete January 30, 2012 July 19, 2012 SR0266-000
Spiriva Respimat Tiotropium bromide Chronic obstructive pulmonary disease List with clinical criteria and/or conditions Complete December 23, 2014 July 16, 2015 SR0412-000
Revatio Sildenafil citrate Pulmonary arterial hypertension (WHO class II and III) List in a similar manner Complete September 20, 2006 February 14, 2007 SR0076-000
Revestive teduglutide Short Bowel Syndrome (SBS), pediatrics Reimburse with clinical criteria and/or conditions Complete May 29, 2019 November 19, 2019 SR0606-000
Revestive Teduglutide Short bowel syndrome Reimburse with clinical criteria and/or conditions Complete November 26, 2015 July 27, 2016 SR0459-000
Revolade Eltrombopag olamine Chronic immune thrombocytopenic purpura Do not list Complete April 26, 2011 October 24, 2011 SR0230-000
Revolade eltrombopag CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Revolade Eltrombopag Thrombocytopenia associated with chronic hepatitis c infection List with criteria/condition Complete March 31, 2014 March 18, 2015 SR0377-000
Rexulti Brexpiprazole schizophrenia Reimburse with clinical criteria and/or conditions Complete February 3, 2017 November 22, 2017 SR0514-000
Reyataz Atazanavir HIV infection List in a similar manner to other drugs in class Complete December 16, 2003 May 27, 2004 SR0002-000
Rinvoq upadacitinib Arthritis, Rheumatoid Reimburse with clinical criteria and/or conditions Complete July 4, 2019 February 4, 2020 SR0614-000
Rinvoq upadacitinib Psoriatic Arthritis, Adults. Active January 4, 2021 SR0658-000
Rituxan Rituximab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete June 26, 2006 February 14, 2007 SR0068-000
Rituxan Rituximab Granulomatosis with polyangiitis and microscopic polyangiitis List with clinical criteria and/or conditions Complete February 24, 2012 August 16, 2012 SR0270-000
Rosiver Ivermectin Rosacea List with criteria/condition Complete April 30, 2015 November 19, 2015 SR0429-000
Ruzurgi amifampridine Lambert-Eaton myasthenic syndrome Active October 5, 2020 SR0660-000
Rybelsus semaglutide diabetes mellitus, type 2 Active November 26, 2020 SR0637-000
Samsca Tolvaptan Hyponatremia, non-hypovolemic Do not list Complete July 3, 2012 February 13, 2013 SR0283-000
Saphris Asenapine Schizophrenia Do not list Complete December 12, 2011 June 14, 2012 SR0262-000
Saphris Asenapine Bipolar I disorder List with clinical criteria and/or conditions Complete December 12, 2011 June 14, 2012 SR0262-001
Sativex Delta-9-tetrahydrocannabinol/cannabidiol Pain, Neuropathic (adjunctive) in MS. Do not list Complete February 27, 2007 September 26, 2007 SR0092-000
Sativex Delta-9-tetrahydrocannabinol/cannabidiol Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) Do not list Complete August 7, 2007 February 20, 2008 SR0106-000
Saxenda liraglutide Chronic weight management in adults Active December 23, 2020 SR0668-000
Sebivo Telbivudine Hepatitis B (chronic) Do not list Complete December 4, 2006 September 26, 2007 SR0088-000
Seebri Glycopyrronium bromide Chronic obstructive pulmonary disease List with criteria/condition Complete November 30, 2012 May 15, 2013 SR0300-000
Segluromet ertugliflozin and metformin hydrochloride Diabetes mellitus, Type 2 Do not reimburse Complete April 30, 2018 January 23, 2019 SR0566-000
Semglee insulin glargine Diabetes mellitus, Type 1 & 2 Withdrawn November 14, 2018 SE0589-000
Sensipar Cinacalcet hydrochloride Secondary hyper-parathyroidism in chronic kidney disease Do not list Complete August 20, 2004 March 23, 2005 SR0018-000
Signifor Pasireotide diaspartate Cushing’s disease Do not list Complete February 27, 2014 February 24, 2015 SR0372-000
Siliq brodalumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete December 14, 2017 June 20, 2018 SR0547-000
Silkis Calcitriol Psoriasis, mild to moderate plaque Do not list Complete March 15, 2010 September 22, 2010 SR0199-000
Simbrinza Brinzolamide / brimonidine Glaucoma and ocular hypertension List Complete November 3, 2014 June 17, 2015 SR0403-000
Simponi Golimumab Arthritis, psoriatic List in a similar manner Complete September 3, 2009 March 17, 2010 SR0195-000
Simponi Golimumab Ankylosing spondylitis List in a similar manner Complete September 3, 2009 March 17, 2010 SR0196-000
Simponi Golimumab Ulcerative colitis Do not list at the submitted price Complete July 12, 2013 March 19, 2014 SR0341-000
Simponi Golimumab Arthritis, Rheumatoid List in a similar manner Complete September 3, 2009 March 17, 2010 SR0174-000
Sivextro Tedizolid phosphate Acute bacterial skin and skin structure infections Withdrawn January 16, 2015 SR0413-000
Skyrizi risankizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete October 22, 2018 May 28, 2019 SR0583-000
Soliqua lixisenatide + insulin glargine Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete May 18, 2018 December 24, 2018 SR0564-000
Soliris Eculizumab Paroxysmal nocturnal hemoglobinuria (PNH) Do not list Complete September 18, 2009 February 18, 2010 SR0176-000
Soliris Eculizumab Atypical hemolytic uremic syndrome Complete February 9, 2015 SF0416-000
Soliris eculizumab Neuromyelitis optica spectrum disorder Reimburse with clinical criteria and/or conditions Complete February 25, 2020 August 19, 2020 SR0640-000
Soliris eculizumab Myasthenia Gravis (gMG), adults Reimburse with clinical criteria and/or conditions Complete April 1, 2020 October 19, 2020 SR0605-000
Soliris Eculizumab Hemolytic Uremic Syndrome, Atypical Do not list Complete January 7, 2013 July 18, 2013 SR0304-000
Somavert Pegvisomant acromegaly Do not list Complete January 25, 2006 August 2, 2006 SR0050-000
Sovaldi Sofosbuvir Hepatitis C, chronic List with criteria/condition Complete October 1, 2013 August 18, 2014 SR0356-000
Sovaldi sofosbuvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete January 6, 2016 May 18, 2016 SF0464-000
Spinraza nusinersen Spinal Muscular Atrophy Reimburse with clinical criteria and/or conditions Complete June 28, 2017 December 22, 2017 SR0525-000
Spinraza Nusinersen Spinal Muscular Atrophy Reimburse with clinical criteria and/or conditions Complete July 24, 2018 February 27, 2019 SR0576-000
Spravato esketamine hydrochloride Major depressive disorder (MDD), adults Do not reimburse Active June 24, 2019 December 16, 2020 SR0621-000
Spriafil Posaconazole Aspergillus and Candida infections Do not list Complete May 24, 2007 January 30, 2008 SR0097-000
Stalevo Carbidopa, levodopa and entacapone Parkinsons Disease List in a similar manner Complete April 15, 2008 October 16, 2008 SR0131-000
Steglatro ertugliflozin Diabetes mellitus, Type 2 Do not reimburse Complete April 30, 2018 January 23, 2019 SR0565-000
Stelara Ustekinumab Psoriasis List with clinical criteria and/or conditions Complete January 7, 2009 June 17, 2009 SR0156-000
Stelara Ustekinumab Arthritis, psoriatic Do not list at the submitted price Complete October 30, 2013 October 20, 2014 SR0359-000
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder Do not list Complete January 25, 2005 September 28, 2005 SR0031-000
Strattera Atomoxetine hydrochloride Attention deficit hyperactivity disorder Complete September 25, 2006 SF0085-000
Strensiq Asfotase alfa Hypophosphatasia, pediatric-onset List with criteria/condition Complete August 21, 2015 March 23, 2016 SR0443-000
Stribild Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Disoproxil Fumarate HIV infection List with criteria/condition Complete November 30, 2012 May 15, 2013 SR0301-000
Sublinox Zolpidem tartrate Insomnia Do not list Complete March 7, 2013 September 25, 2013 SR0314-000
Sublocade buprenorphine Opioid use disorder, treatment Reimburse with clinical criteria and/or conditions Complete December 20, 2018 June 19, 2019 SR0579-000
Suboxone Buprenorphine/naloxone Opioid drug dependence (Substitution treatment) List with clinical criteria and/or conditions Complete March 6, 2008 September 24, 2008 SR0128-000
Sunvepra Asunaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete February 13, 2015 July 20, 2016 SR0418-000
Sutent Sunitinib Gastrointestinal stromal tumour (GIST) List with clinical criteria and/or conditions Complete July 20, 2006 March 28, 2007 SR0069-000
Sutent Sunitinib malate Cancer, Metastatic renal cell carcinoma Do not list Complete September 20, 2006 April 26, 2007 SR0077-000
Symdeko tezacaftor/ivacaftor CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Symtuza Darunavir/cobicistat/emtricitabine/tenofovir alafenamide HIV-1 infection Reimburse with clinical criteria and/or conditions Complete December 22, 2017 July 25, 2018 SR0552-000
Synjardy Empagliflozin and metformin Diabetes mellitus (Type 2) Reimburse with clinical criteria and/or conditions Complete April 29, 2016 October 25, 2016 SR0489-000
Tagrisso osimertinib Non-small cell lung cancer Pending PC0246-000
Takhzyro lanadelumab Hereditary angioedema, prevention Reimburse with clinical criteria and/or conditions Complete May 29, 2019 November 19, 2019 SR0618-000
Taltz ixekizumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete September 20, 2019 March 24, 2020 SR0630-000
Taltz ixekizumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete February 20, 2018 August 21, 2018 SR0558-000
Taltz Ixekizumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete March 23, 2016 October 25, 2016 SR0481-000
Talzenna talazoparib Breast cancer CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Tarceva Erlotinib Cancer, Lung , non-small cell List with clinical criteria and/or conditions Complete July 19, 2005 December 7, 2005 SR0037-000
Targin Oxycodone / naloxone Pain, Moderate to severe and relief of opioid-induced constipation Cancelled November 30, 2010 SR0219-000
Targin Oxycodone HCI / naloxone HCI Pain, moderate to severe and relief of opioid-induced constipation Do not list Complete July 5, 2011 January 25, 2012 SR0241-000
TBC Darunavir / cobicistat HIV infection Withdrawn April 4, 2014 SR0378-000
TBC idecabtagene vicleucel Multiple myeloma Active December 16, 2020 PG0240-000
TBC brexucabtagene autoleucel Mantle cell lymphoma Active December 18, 2020 PG0219-000
TBC triheptanoin Long-chain fatty acid oxidation disorders Pending SR0684-000
TBC risdiplam Spinal muscular atrophy Active November 19, 2020 SR0661-000
TBC budesonide/ glycopyrronium /formoterol fumarate chronic obstructive pulmonary disease (COPD) Active January 28, 2021 SR0675-000
TBC filgotinib Arthritis, Rheumatoid Withdrawn August 4, 2020 SR0656-000
TBC inclisiran Primary hypercholesterolemia Pending SR0681-000
TBC etonogestrel Prevention of pregnancy Withdrawn September 26, 2019 SR0629-000
TBC filgrastim Prevention or treatment of neutropenia in various indications Cancelled November 1, 2018 SE0585-000
TBC filgrastim Cancelled SE0596-000
TBC elexacaftor/tezacaftor/ivacaftor and ivacaftor Cystic fibrosis, F508del CFTR mutation Active January 22, 2021 SR0673-000
TBC halobetasol propionate and tazarotene Psoriasis, moderate to severe plaque Withdrawn February 4, 2019 SR0600-000
TBC ravulizumab Paroxysmal nocturnal hemoglobinuria. Withdrawn July 4, 2019 SR0623-000
Tecfidera Dimethyl fumarate Multiple sclerosis, relapsing-remitting List with criteria/condition Complete February 4, 2013 September 25, 2013 SR0309-000
Technivie Ombitasvir/ paritaprevir/ ritonavir Hepatitis C, chronic List with clinical criteria and/or conditions Complete September 4, 2015 March 18, 2016 SR0444-000
Tegsedi inotersen hereditary transthyretin amyloidosis Reimburse with clinical criteria and/or conditions Complete February 22, 2019 December 18, 2019 SR0603-000
Telzir Fosamprenavir calcium HIV infection List in a similar manner to other drugs in class Complete January 24, 2005 June 16, 2005 SR0030-000
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete May 5, 2008 January 28, 2009 SR0132-000
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete June 22, 2007 January 30, 2008 SR0099-000
Tivicay Dolutegravir HIV infection List Complete October 18, 2013 August 18, 2014 SR0357-000
Toctino Alitretinoin Eczema List with clinical criteria and/or conditions Complete May 6, 2011 October 24, 2011 SR0232-000
Toviaz Fesoterodine fumarate Overactive bladder List in a similar manner Complete April 27, 2012 October 18, 2012 SR0277-000
Trajenta Linagliptin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete August 23, 2011 February 15, 2012 SR0244-000
Tramacet Tramadol hydrochloride /acetaminophen Acute pain Do not list Complete October 2, 2006 May 17, 2007 SR0079-000
Translarna ataluren Cancelled SR0607-000
Trelstar Triptorelin pamoate Cancer, prostate List in a similar manner to other drugs in class Complete February 27, 2006 July 20, 2006 SR0051-000
Tremfya guselkumab Psoriasis, moderate to severe plaque Reimburse with clinical criteria and/or conditions Complete August 25, 2017 February 21, 2018 SR0530-000
Tresiba insulin degludec Diabetes mellitus, Type 1 & 2 Reimburse with clinical criteria and/or conditions Complete May 31, 2017 November 20, 2017 SR0521-000
Tridural Tramadol hydrochloride Pain Do not list Complete November 29, 2007 April 17, 2008 SR0117-000
Trintellix vortioxetine hydrobromide Major depressive disorder (MDD), adults. Reimburse with clinical criteria and/or conditions Complete May 1, 2019 February 12, 2020 SR0611-000
Trintellix Vortioxetine Depression, major depressive disorder Withdrawn October 31, 2014 SR0402-000
Triumeq Dolutegravir / abacavir / lamivudine HIV Infection List with criteria/condition Complete July 31, 2014 April 17, 2015 SR0387-000
Trosec Trospium chloride Bladder, overactive List with clinical criteria and/or conditions Complete March 24, 2006 August 24, 2006 SR0055-000
Trulicity Dulaglutide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete December 22, 2015 June 16, 2016 SR0462-000
Truvada Emtricitabine/tenofovir disoproxil fumarate HIV infection List with clinical criteria and/or conditions Complete May 29, 2006 October 25, 2006 SR0063-000
Truvada Emtricitabine/tenofovir disoproxil fumarate HIV infection List with clinical criteria and/or conditions Complete July 7, 2008 December 17, 2008 SF0138-000
Truvada Emtricitabine/tenofovir disoproxil fumarate HIV-1 infection, pre-exposure prophylaxis Reimburse with clinical criteria and/or conditions Complete March 3, 2016 August 24, 2016 SR0479-000
Tukysa tucatinib Advanced or Metastatic Breast Cancer Pending PC0243-000
Twynsta Telmisartan/ Amlodipine Hypertension List Complete August 23, 2011 December 16, 2011 SR0245-000
Twynsta Telmisartan / Amlodipine Hypertension Cancelled July 9, 2010 SR0207-000
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting List with clinical criteria and/or conditions Complete May 6, 2008 February 25, 2009 SR0133-000
Tysabri Natalizumab Multiple Sclerosis, relapsing-remitting Do not list Complete October 26, 2006 April 26, 2007 SR0082-000
Uloric Febuxostat Gout List with clinical criteria and/or conditions Complete October 27, 2010 April 25, 2011 SR0213-000
Unituxin dinutuximab Neuroblastoma Active November 23, 2020 PC0222-000
Uptravi Selexipag Pulmonary arterial hypertension (WHO class II and III) Reimburse with clinical criteria and/or conditions Complete March 31, 2016 October 28, 2016 SR0482-000
Vantas Histrelin acetate Cancer, prostate Do not list Complete September 20, 2006 April 26, 2007 SR0078-000
Vascepa icosapent ethyl Ischemic events in statin-treated patients Reimburse with clinical criteria and/or conditions Complete June 17, 2019 July 16, 2020 SR0619-000
Velphoro sucroferric oxyhydroxide Hyperphosphatemia, end-stage renal disease Reimburse with clinical criteria and/or conditions Complete June 12, 2018 January 2, 2019 SR0571-000
Veltassa patiromer Hyperkalemia, adults (chronic kidney disease) Active October 30, 2020 SR0665-000
Vemlidy tenofovir alafenamide Hepatitis B, chronic Reimburse with clinical criteria and/or conditions Complete September 28, 2017 March 26, 2018 SR0537-000
Venclexta venetoclax Acute myeloid leukemia Active January 8, 2021 PC0238-000
Venclexta venetoclax Acute myeloid leukemia Active January 22, 2021 PC0239-000
Verkazia cyclosporine Severe vernal keratoconjunctivitis, pediatric (≥4 years) Reimburse with clinical criteria and/or conditions Complete May 22, 2019 November 18, 2019 SR0615-000
Vesicare Solifenacin succinate Bladder, overactive List with clinical criteria and/or conditions Complete January 5, 2009 June 17, 2009 SR0155-000
Vesicare Solifenacin succinate Bladder, overactive Do not list Complete July 24, 2006 January 24, 2007 SR0070-000
VesiFlow Solifenacin succinate / tamsulosin hydrochloride Benign prostatic hyperplasia Withdrawn April 6, 2015 SR0424-000
VFEND Voriconazole Aspergillosis, Invasive List with clinical criteria and/or conditions Complete October 25, 2004 April 14, 2005 SR0023-000
VFEND Voriconazole Candidemia List with clinical criteria and/or conditions Complete March 24, 2006 October 25, 2006 SR0056-000
VFEND Voriconazole Aspergillosis, Invasive Withdrawn August 24, 2004 SR0020-000
Viacoram perindopril arginine / amlodipine Hypertension, essential Reimburse with clinical criteria and/or conditions Complete May 2, 2016 October 26, 2016 SR0490-000
Viberzi eluxadoline Irritable bowel syndrome with diarrhea Do not reimburse Complete February 23, 2018 August 24, 2018 SR0560-000
Victoza Liraglutide Diabetes Mellitus, Type 2 Withdrawn October 20, 2016 SR0505-000
Victoza Liraglutide Diabetes mellitus, Type 2 Do not list Complete November 29, 2010 September 28, 2011 SR0217-000
Victrelis Boceprevir Hepatitis C, chronic List with criteria/condition Complete December 21, 2012 June 13, 2013 SF0303-000
Victrelis Boceprevir Hepatitis C, chronic List with criteria/condition Complete February 19, 2013 June 13, 2013 SF0312-000
Victrelis Boceprevir Hepatitis C, chronic List with clinical criteria and/or conditions Complete May 3, 2011 October 24, 2011 SR0231-000
Viibryd vilazodone CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Vimizim Elosulfase alfa Mucopolysaccharidosis IVA (Morquio A syndrome) Do not list Complete August 5, 2014 March 25, 2015 SR0389-000
Vimizim Elosulfase alfa Mucopolysaccharidosis IVA (Morquio A syndrome) Reimburse with clinical criteria and/or conditions Complete November 10, 2015 May 20, 2016 SR0456-000
Vimpat Lacosamide Epilepsy, partial onset seizures List with clinical criteria and/or conditions Complete October 25, 2010 April 25, 2011 SR0212-000
Viread Tenofovir disoproxil fumarate HIV infection Complete July 7, 2008 SF0139-000
Viread Tenofovir disoproxil fumarate Hepatitis B (chronic) List with clinical criteria and/or conditions Complete October 2, 2008 March 18, 2009 SR0148-000
Viread Tenofovir disoproxil fumarate HIV infection Do not list Complete February 23, 2004 August 25, 2004 SR0008-000
Viread Tenofovir disoproxil fumarate HIV infection List with clinical criteria and/or conditions Complete August 11, 2005 March 15, 2006 SR0040-000
Visanne Dienogest Pain, pelvic pain associated with endometriosis List with clinical criteria and/or conditions Complete October 18, 2011 April 19, 2012 SR0255-000
Vitrakvi larotrectinib Solid tumours with NTRK gene fusion Active November 16, 2020 PC0221-000
Volibris Ambrisentan Pulmonary arterial hypertension (WHO class II and III) List with clinical criteria and/or conditions Complete July 9, 2008 December 17, 2008 SR0142-000
Vonvendi von Willebrand Factor [recombinant] von Willebrand disease, adults, treatment and perioperative management Active April 29, 2020 ST0639-000
Vosevi sofosbuvir velpatasvir voxilaprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete July 28, 2017 January 23, 2018 SR0529-000
VPRIV Velaglucerase alfa Gaucher Disease List with clinical criteria and/or conditions Complete October 28, 2010 April 25, 2011 SR0215-000
Vyndaqel tafamidis transthyretin-mediated amyloidosis Reimburse with clinical criteria and/or conditions Complete July 4, 2019 February 19, 2020 SR0625-000
Vyvanse Lisdexamfetamine dimesylate Attention deficit hyperactivity disorder Do not list Complete July 10, 2009 December 18, 2009 SR0171-000
Vyxeos daunorubicin and cytarabine Acute myeloid leukemia Active January 22, 2021 PC0237-000
Vyzulta latanoprostene bunod Open-angle glaucoma or ocular hypertension Reimburse with clinical criteria and/or conditions Complete November 23, 2018 July 24, 2019 SR0590-000
Xarelto Rivaroxaban Venous thromboembolism, prevention Complete June 24, 2011 SF0239-000
Xarelto Rivaroxaban Thromboembolism (venous), prevention List with clinical criteria and/or conditions Complete May 7, 2008 December 17, 2008 SR0134-000
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism Complete October 10, 2012 SF0295-000
Xarelto rivaroxaban Prevention of stroke and cardiovascular events in coronary and peripheral artery disease. Reimburse with clinical criteria and/or conditions Complete May 24, 2018 November 20, 2018 SR0569-000
Xarelto Rivaroxaban List with clinical criteria and/or conditions Complete March 18, 2013 July 18, 2013 SF0321-00
Xarelto Rivaroxaban Venous thromboembolic events, pulmonary embolism List with criteria/condition Complete May 6, 2013 March 26, 2014 SR0327-000
Xarelto Rivaroxaban Atrial fibrillation, stroke prevention List with clinical criteria and/or conditions Complete October 21, 2011 April 19, 2012 SR0257-000
Xarelto Rivaroxaban Deep-vein thrombosis without symptomatic pulmonary embolism List with clinical criteria and/or conditions Complete February 27, 2012 August 16, 2012 SR0271-000
Xeljanz Tofacitinib Arthritis, rheumatoid List with criteria/condition Complete May 5, 2014 April 17, 2015 SR0380-000
Xeljanz tofacitinib Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete June 27, 2018 February 27, 2019 SR0572-000
Xeljanz tofacitinib Cancelled SR0575-000
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Blepharospasm List in a similar manner Complete June 12, 2009 December 16, 2009 SR0168-000
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Cervical Dystonia List in a similar manner Complete June 12, 2009 December 16, 2009 SR0192-000
Xeomin Clostridium botulinum neurotoxin type A, free from complexing proteins Spasticity, Post-stroke Do not list Complete June 12, 2009 December 16, 2009 SR0193-000
Xeomin incobotulinumtoxin A Chronic sialorrhea associated with neurological disorders Pending SR0678-000
Xermelo telotristat carcinoid syndrome Do not reimburse Complete September 27, 2018 June 26, 2019 SR0580-000
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from breast cancer List with clinical criteria and/or conditions Complete July 31, 2015 February 25, 2016 SR0433-000
Xgeva Denosumab (Drug Plan Submission) Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer List with clinical criteria and/or conditions Complete July 31, 2015 March 23, 2016 SR0433-001
XGEVA Denosumab Prevention of skeletal-related events due to bone metastases from solid tumours List with clinical criteria and/or conditions Complete June 6, 2011 November 16, 2011 SR0235-000
Xiaflex Collagenase clostridium histolyticum Dupuytren’s contracture List with criteria/condition Complete August 30, 2012 March 27, 2013 SR0287-000
XigDuo dapagliflozin/metformin hydrochloride Diabetes Mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete January 7, 2016 July 20, 2016 SR0468-000
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn November 3, 2006 SR0086-000
Zytram XL Tramadol hydrochloride Pain, acute Do not list Complete March 15, 2007 September 26, 2007 SR0093-000
Xofluza baloxavir marboxil Influenza CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Xolair Omalizumab Chronic idiopathic urticaria List with clinical criteria and/or conditions Complete September 22, 2014 May 7, 2015 SR0398-000
Xolair Omalizumab Asthma, severe persistent Cancelled April 18, 2005 SR0035-000
Xolair Omalizumab (Drug Plan Submission) Asthma, severe persistent Reimburse with clinical criteria and/or conditions Complete November 18, 2015 May 18, 2016 SR0457-000
Xolair Omalizumab Asthma, severe persistent Do not list Complete October 13, 2005 March 7, 2006 SR0045-000
Xultophy insulin degludec + liraglutide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete January 30, 2019 October 24, 2019 SR0599-000
Xyrem Sodium oxybate Narcolepsy Do not list Complete July 9, 2008 January 28, 2009 SR0141-000
Xyrem Sodium oxybate Narcolepsy Withdrawn August 29, 2007 SR0107-000
Yasmin Drospirenone /ethinyl estradiol Contraceptive, oral List Complete January 20, 2005 June 16, 2005 SR0029-000
Zavesca Miglustat Gaucher disease Do not list Complete May 13, 2004 November 24, 2004 SR0012-000
Zaxine Rifaximin Hepatic encephalopathy List with criteria/condition Complete August 5, 2014 April 16, 2015 SR0388-000
Zeldox Ziprasidone hydrochloride Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete January 10, 2008 August 14, 2008 SR0124-000
Zenhale Mometasone/formoterol Asthma List with clinical criteria and/or conditions Complete June 6, 2012 December 19, 2012 SF0281-000
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete October 27, 2015 May 19, 2016 SR0454-000
Zeposia ozanimod Multiple Sclerosis, relapsing - remitting Active August 25, 2020 SR0652-000
Zinbryta Daclizumab beta Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete December 20, 2016 June 20, 2017 SR0508-000
Zolgensma onasemnogene abeparvovec Spinal muscular atrophy (SMA), pediatrics Active June 25, 2020 SG0649-000
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer NotFiled
Opdivo Nivolumab Metastatic non small cell lung cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 29, 2015 June 3, 2016 PC0069-000
Blincyto Blinatumomab Acute Lymphoblastic Leukemia Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 24, 2015 April 1, 2016 PC0064-000
Jakavi Ruxolitinib Polycythemia vera Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 27, 2015 March 3, 2016 PC0065-000
Adcetris Brentuximab vedotin Notification to Implement Issued March 15, 2013 December 5, 2013 PC0021-000
Arzerra Ofatumumab Notification to Implement Issued April 14, 2014 January 29, 2015 PC0038-000
Giotrif Afatinib Notification to Implement Issued June 7, 2013 May 2, 2014 PC0032-000
Kadcyla Trastuzumab emtansine Notification to Implement Issued March 15, 2013 January 10, 2014 PC0024-000
Nexavar Sorafenib Notification to Implement Issued December 19, 2014 July 16, 2015 PC0049-000
Revlimid Lenalidomide Notification to Implement Issued April 5, 2013 October 22, 2013 PC0029-000
Treanda (in combination with rituximab) Bendamustine hydrochloride Withdrawn June 27, 2014 PC0040-000
Tykerb (in combination with Letrozole) Lapatinib Notification to Implement Issued December 14, 2012 July 5, 2013 PC0019-000
Votrient Pazopanib hydrochloride Notification to Implement Issued Resubmission Complete July 14, 2011 January 5, 2012 PC0000-000
Xalkori Crizotinib Notification to Implement Issued February 17, 2015 July 21, 2015 PC0054-000
Zytiga Abiraterone acetate Notification to Implement Issued March 28, 2013 October 22, 2013 PC0028-000
Adcetris Brentuximab vedotin Withdrawn April 5, 2016 PC0086-000
Onivyde Nanoliposomal Irinotecan File-Closed Not Submitted PC0096-000
Mylotarg Gemtuzumab Ozogamicin Acute Myeloid Leukemia (AML) Notification to Implement Issued August 9, 2019 April 2, 2020 PC0190-000
Bosulif (RFA) Bosutinib Chronic Myeloid Leukemia Notification to Implement Issued April 8, 2019 PA0002-000
Unituxin Dinutuximab Neuroblastoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 1, 2018 March 26, 2019 PC0154-000
Xalkori Crizotinib ROS1-positive advanced non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 30, 2018 May 23, 2019 PC0151-000
Keytruda Pembrolizumab Nonsquamous NSCLC Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 14, 2018 May 31, 2019 PC0153-000
Keytruda Pembrolizumab MUC First line Do not reimburse Notification to Implement Issued February 20, 2019 October 3, 2019 PC0177-000
TBD Rituximab File-Closed Not Submitted PC0180-000
Opdivo Nivolumab Metastatic Hepatocellular Carcinoma (HCC) Do not reimburse Notification to Implement Issued May 8, 2018 November 29, 2018 PC0134-000
Blincyto Blinatumomab Withdrawn June 29, 2018 PC0143-000
Revlimid Lenalidomide Multiple Myeloma (+bortezomib+dex) Do not reimburse Notification to Implement Issued June 19, 2019 PC0141-000
Lenvima Lenvatinib Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued February 8, 2019 July 24, 2019 PC0175-000
Vectibix Panitumumab Left Sided Metastatic Colorectal Cancer (mCRC) Do not reimburse Notification to Implement Issued September 8, 2017 March 29, 2018 PC0118-000
Gazyva Obinutuzumab Follicular Lymphoma (previously untreated) Do not reimburse Notification to Implement Issued March 15, 2018 November 1, 2018 PC0126-000
Darzalex Daratumumab Multiple Myeloma Do not reimburse Notification to Implement Issued April 21, 2016 December 1, 2016 PC0079-000
Lynparza (Resubmission) Olaparib Ovarian Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued March 17, 2017 September 20, 2017 PC0103-000
Opdivo Nivolumab Squamous Cell Carcinoma of Head and Neck (SCCHN) Reimburse with clinical criteria and/or conditions Notification to Implement Issued January 31, 2017 August 31, 2017 PC0095-000
Ninlaro Ixazomib Multiple Myeloma Do not reimburse Notification to Implement Issued December 16, 2016 June 29, 2017 PC0088-000
Imbruvica Ibrutinib Not Filed
Kisqali Ribociclib HR+, HER2- advanced or metastatic breast cancer Notification to Implement Issued August 26, 2019 June 4, 2020 PC0194-000
Lonsurf Trifluridine-Tipiracil Gastric Cancer Notification to Implement Issued September 3, 2019 March 24, 2020 PC0197-000
Odomzo Sonidegib Basal Cell Carcinoma Under Review June 19, 2020 PC0215-000
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab NSCLC Under Review June 23, 2020 PC0218-000
Cabometyx Cabozantinib HCC Notification to Implement Issued October 16, 2019 April 22, 2020 PC0186-000
Rozlytrek Entrectinib ROS1-positive NSCLC Notification to Implement Issued January 8, 2020 January 27, 2021 PC0206-000
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) Notification to Implement Issued April 7, 2020 November 17, 2020 PC0211-000
Alecensaro Alectinib Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 18, 2017 March 29, 2018 PC0114-000
Bavencio Avelumab metastatic Merkel Cell Carcinoma (mMCC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 10, 2017 March 21, 2018 PC0124-000
Kyprolis Carfilzomib Multiple Myeloma (relapsed) Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 9, 2016 March 30, 2017 PC0084-000
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Early Breast Cancer Do not reimburse Notification to Implement Issued April 9, 2018 November 29, 2018 PC0127-000
Erbitux Cetuximab File-Closed Not Submitted PC0128-000
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Non-Small Cell Lung Cancer Do not reimburse Notification to Implement Issued March 31, 2017 November 2, 2017 PC0106-000
Vizimpro Dacomitinib Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 19, 2018 May 31, 2019 PC0129-000
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Melanoma Adjuvant Therapy Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 21, 2018 May 3, 2019 PC0152-000
Ibrance (with Faslodex) Palbociclib (with Fulvestrant) Palbociclib (Ibrance) in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 28, 2018 May 3, 2019 PC0150-000
Velcade Bortezomib Notification to Implement Issued October 29, 2012 March 25, 2013 PC0016-000
Votrient Pazopanib hydrochloride Notification to Implement Issued Original Submission Complete February 20, 2013 August 29, 2013 PC0022-000
Xtandi Enzalutamide Notification to Implement Issued October 2, 2014 June 22, 2015 PC0044-000
Avastin Bevacizumab Notification to Implement Issued October 27, 2014 March 23, 2015 PC0045-000
Adcetris Brentuximab vedotin Notification to Implement Issued March 14, 2013 August 29, 2013 PC0020-000
Avastin (with capecitabine) Bevacizumab Notification to Implement Issued February 18, 2015 July 21, 2015 PC0055-000
Bosulif Bosutinib Notification to Implement Issued May 30, 2014 April 21, 2015 PC0039-000
Halaven Eribulin Mesylate Notification to Implement Issued February 9, 2012 August 2, 2012 PC0005-000
Perjeta Herceptin Combo Pack Pertuzumab Notification to Implement Issued November 2, 2012 August 1, 2013 PC0018-000
Stivarga (CRC) Regorafenib Notification to Implement Issued March 22, 2013 November 15, 2013 PC0026-000
Treanda Bendamustine hydrochloride Notification to Implement Issued April 24, 2012 November 29, 2012 PC0011-000
Imbruvica Ibrutinib Mantle Cell Lymphoma (relapsed/refractory) Reimburse with clinical criteria and/or conditions Notification to Implement Issued January 29, 2016 July 19, 2016 PC0073-000
Afinitor Everolimus Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin Reimburse with clinical criteria and/or conditions Notification to Implement Issued May 30, 2016 December 1, 2016 PC0083-000
Zydelig Idelalisib Follicular Lymphoma Do not reimburse Notification to Implement Issued April 12, 2016 September 29, 2016 PC0075-000
Vectibix Panitumumab Notification to Implement Issued April 15, 2015 December 3, 2015 PC0060-000
Lutathera Lutetium Lu 177 dotatate Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Reimburse with clinical criteria and/or conditions Notification to Implement Issued July 30, 2018 August 1, 2019 PC0142-000
Zejula Niraparib Ovarian Cancer Notification to Implement Issued February 7, 2020 September 3, 2020 PC0203-000
Lynparza Olaparib Newly Diagnosed OC Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 18, 2019 December 5, 2019 PC0174-000
Ninlaro Ixazomib Multiple Myeloma (2nd-beyond) Do not reimburse Notification to Implement Issued November 30, 2018 July 5, 2019 PC0164-000
Keytruda Pembrolizumab Melanoma Adjuvant Treatment Reimburse with clinical criteria and/or conditions Notification to Implement Issued December 13, 2018 August 1, 2019 PC0168-000
Ogivri Trastuzumab Withdrawn December 18, 2018 PC0169-000
Adcetris Brentuximab Vedotin peripheral T-cell lymphoma (PTCL) Notification to Implement Issued October 8, 2019 June 4, 2020 PC0199-000
Xospata Gilteritinib Notification to Implement Issued October 28, 2019 May 20, 2020 PC0202 -000
Nubeqa Darolutamide non-metastatic castration resistant prostate cancer (nmCRPC) Notification to Implement Issued August 27, 2019 April 22, 2020 PC0196-000
Atriance Nelarabine File-Closed Not Submitted PC0170-000
Idhifa Enasidenib Acute myeloid leukemia (AML) Do not reimburse Notification to Implement Issued April 5, 2019 October 31, 2019 PC0144-000
Oncaspar Pegaspargase Not Filed
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Suspended July 29, 2019 PC0201-000
Daurismo Glasdegib Acute Myeloid Leukemia (AML) Notification to Implement Issued May 6, 2020 January 8, 2021 PC0207-000
Afinitor Everolimus Notification to Implement Issued February 27, 2012 August 30, 2012 PC0007-000
Avastin Bevacizumab Notification to Implement Issued November 28, 2014 June 4, 2015 PC0047-000
Erbitux Cetuximab Notification to Implement Issued June 10, 2013 January 10, 2014 PC0031-000
Inlyta Axitinib Notification to Implement Issued August 16, 2012 March 7, 2013 PC0013-000
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Notification to Implement Issued December 19, 2014 July 16, 2015 PC0050-000
Stivarga (GIST) Regorafenib Notification to Implement Issued October 11, 2013 May 2, 2014 PC0034-000
Sutent Sunitinib malate Notification to Implement Issued November 7, 2011 May 3, 2012 PC0004-000
Treanda Bendamustine hydrochloride Notification to Implement Issued April 24, 2012 February 19, 2013 PC0011-000
Votrient Pazopanib Hydrochloride Notification to Implement Issued June 4, 2012 November 29, 2012 PC0009-000
Xtandi Enzalutamide Notification to Implement Issued March 4, 2013 July 23, 2013 PC0023-000
Imbruvica Ibrutinib Notification to Implement Issued August 15, 2014 March 5, 2015 PC0043-000
Verzenio Abemaciclib Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued December 3, 2018 July 5, 2019 PC0161-000
Zytiga Abiraterone Withdrawn February 25, 2019 PC0166-000
Darzalex Daratumumab BMP for Multiple Myeloma (newly diagnosed) Reimburse with clinical criteria and/or conditions Notification to Implement Issued January 4, 2019 August 29, 2019 PC0148-000
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Notification to Implement Issued January 15, 2018 July 25, 2018 PC0125-000
Lenvima Lenvatinib Notification to Implement Issued June 8, 2018 January 4, 2019 PC0140 -000
Demylocan Decitabine Not Filed
Kadcyla Trastuzumab Emtansine Early Breast Cancer (EBC) Reimburse Notification to Implement Issued July 2, 2019 January 22, 2020 PC0182-000
Truxima Rituximab File-Closed Not Submitted PC0184-000
Stivarga Regorafenib Unresectable Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 12, 2017 April 18, 2018 PC0119-000
Kisqali Ribociclib Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 17, 2017 April 18, 2018 PC0112-000
Tecentriq Atezolizumab Small Cell Lung Cancer (SCLC) Do not reimburse Notification to Implement Issued March 4, 2019 January 30, 2020 PC0156-000
Lonsurf Trifluridine and Tipiracil Metastatic Colorectal Cancer Do not reimburse Notification to Implement Issued November 6, 2017 July 6, 2018 PC0122-000
Folotyn Pralatrexate Peripheral T-Cell Lymphoma (PTCL) Reimburse with clinical criteria and/or conditions Notification to Implement Issued June 1, 2018 April 4, 2019 PC0138-000
Tecentriq & Avastin Atezolizumab & Bevacizumab NSQ-NSCLC Notification to Implement Issued November 18, 2019 July 3, 2020 PC0155-000
Venclexta Venetoclax Obinutuzumab Obinutuzumab for CLL Notification to Implement Issued April 17, 2020 November 17, 2020 PC0212-000
Keytruda Pembrolizumab Not Filed
Rydapt Midostaurin Systemic Mastocytosis Notification to Implement Issued August 13, 2019 April 2, 2020 PC0193-000
Imbruvica Ibrutinib Not Filed
Darzalex Daratumumab Rd for MM Notification to Implement Issued July 17, 2019 March 5, 2020 PC0189-000
TBD Trastuzumab File-Closed Not Submitted PC0160-000
Inlyta (RFA) Axitinib Metastatic Renal Cell Carcinoma Notification to Implement Issued April 18, 2017 PA0001-000
Keytruda Pembrolizumab classical Hodgkin Lymphoma (cHL) Reimburse with clinical criteria and/or conditions Notification to Implement Issued July 7, 2017 January 5, 2018 PC0109-000
Rydapt Midostaurin Acute Myeloid Leukemia Reimburse Notification to Implement Issued June 12, 2017 December 19, 2017 PC0108-000
Ibrance Resubmission Palbociclib Advanced breast cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued June 10, 2016 November 21, 2016 PC0093-000
Opdivo & Yervoy in combo Nivolumab & Ipilimumab in combo Metastatic Melanoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued November 30, 2016 November 30, 2017 PC0098-000
Gazyva Obinutuzumab Follicular Lymphoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued November 4, 2016 June 2, 2017 PC0091-000
Tagrisso Osimertinib Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 1, 2016 May 4, 2017 PC0076-000
Zykadia Ceritinib Notification to Implement Issued June 5, 2015 December 3, 2015 PC0062-000
Opdivo Nivolumab Metastatic Melanoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 13, 2015 April 1, 2016 PC0063-000
Opdivo Nivolumab Metastatic Renal Cell Carcinoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued February 24, 2016 September 1, 2016 PC0074-000
Blincyto Blinatumomab Notification to Implement Issued February 24, 2017 August 23, 2017 PC0099 -000
Polivy Polatuzumab Vedotin Diffuse large B-cell lymphoma (DLBCL) Under Review September 29, 2020 PC0227-000
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Under Review September 30, 2020 PC0230-000
Afinitor Everolimus Notification to Implement Issued September 5, 2012 March 25, 2013 PC0014-000
Erivedge Vismodegib Notification to Implement Issued June 14, 2013 January 10, 2014 PC0015-000
Istodax Romidepsin Notification to Implement Issued December 1, 2014 May 19, 2015 PC0048-000
Pomalyst Pomalidomide Notification to Implement Issued January 13, 2014 July 31, 2014 PC0036-000
Stivarga Resubmission (CRC) Regorafenib Notification to Implement Issued December 19, 2014 July 16, 2015 PC0046-000
Sylvant Siltuximab Notification to Implement Issued January 30, 2015 June 22, 2015 PC0052-000
Treanda Bendamustine hydrochloride Notification to Implement Issued April 24, 2012 November 29, 2012 PC0010-000
Xalkori Crizotinib Notification to Implement Issued Original Submission Complete March 26, 2012 October 4, 2012 PC0008-000
Yervoy Ipilimumab Notification to Implement Issued December 1, 2011 April 18, 2012 PC0003-000
Zaltrap Aflibercept Notification to Implement Issued November 26, 2013 September 5, 2014 PC0035-000
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Notification to Implement Issued February 13, 2015 July 21, 2015 PC0053-000
Zykadia (Resubmission) Ceritinib metastatic non-small cell lung cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 19, 2016 March 21, 2017 PC0094-000
Lorbrena Lorlatinib Non-Small Cell Lung Cancer (NSCLC) Do not reimburse Notification to Implement Issued June 11, 2019 January 30, 2020 PC0183-000
Zevalin Ibritumomab tiuxetan Not Filed
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab Advanced or Metastatic Renal Cell Carcinoma (RCC). Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 26, 2018 November 1, 2018 PC0132-000
Erleada Apalutamide non-metastatic castrate resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 16, 2018 November 1, 2018 PC0133-000
Kisqali Ribociclib with Fulvestrant +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer Notification to Implement Issued August 26, 2019 April 22, 2020 PC0195-000
Tecentriq Atezolizumab Withdrawn October 2, 2019 PC0171-000
Keytruda Pembrolizumab For locally advanced or metastatic urothelial carcinoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued July 24, 2017 March 2, 2018 PC0117-000
Venclexta in combo Rituximab Venetoclax Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 24, 2018 May 31, 2019 PC0162-000
Opdivo Nivolumab Melanoma Adjuvant Therapy Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 27, 2018 March 7, 2019 PC0147-000
Imfinzi Durvalumab Unresectable Non-Small Cell Lung Cancer (NSCLC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 21, 2018 May 3, 2019 PC0131-000
Keytruda Pembrolizumab Squamous NSCLC Reimburse with clinical criteria and/or conditions Notification to Implement Issued February 8, 2019 January 3, 2020 PC0176-000
Tecentriq Atezolizumab Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued December 15, 2017 June 20, 2018 PC0115-000
Vitrakvi Larotrectinib NTRKplus solid tumours Do not reimburse Notification to Implement Issued February 25, 2019 October 31, 2019 PC0159-000
TBD Bevacizumab File Closed March 14, 2019 PC0178-000
Imbruvica Ibrutinib Chronic Lymphocytic Leukemia (previously untreated) Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 20, 2016 November 3, 2016 PC0085-000
Venclexta Venetoclax Withdrawn July 8, 2016 PC0087-000
Lenvima Lenvatinib Differentiated Thyroid Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 18, 2016 September 20, 2016 PC0080-000
Imbruvica Ibrutinib Waldenstrom's Macroglobulinemia Do not reimburse Pending April 21, 2016 November 3, 2016 PC0082-000
Caprelsa Vandetanib Medullary Thyroid Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 15, 2016 March 30, 2017 PC0090-000
Keytruda Pembrolizumab Notification to Implement Issued April 16, 2015 November 16, 2015 PC0058-000
Yondelis Trabectedin Metastatic Liposarcoma or Leiomyosarcoma Do not reimburse Notification to Implement Issued December 22, 2015 August 5, 2016 PC0071-000
Cotellic Cobimetinib Metastatic melanoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued December 11, 2015 June 30, 2016 PC0070-000
Kyprolis (with lenalidomide) Carfilzomib (with lenalidomide) Multiple Myeloma Reimburse with clinical criteria and/or conditions Notification to Implement Issued December 11, 2015 June 21, 2016 PC0067-000
Lartruvo Olaratumab Advanced Soft Tissue Sarcoma Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 26, 2017 April 18, 2018 PC0111-000
Opdivo Nivolumab classical Hodgkin Lymphoma (cHL) after failure of ASCT Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 29, 2017 May 3, 2018 PC0120-000
Darzalex Daratumumab Multiple Myeloma (second-line) Reimburse with clinical criteria and/or conditions Notification to Implement Issued March 3, 2017 October 5, 2017 PC0104-000
Adcetris Brentuximab Vedotin Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) Notification to Implement Issued April 2, 2020 December 3, 2020 PC0214-000
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Notification to Implement Issued April 7, 2020 January 8, 2021 PC0210-000
Tecentriq & Avastin Atezolizumab & Bevacizumab Hepatocellular Carcinoma (HCC) Notification to Implement Issued May 21, 2020 November 17, 2020 PC0217-000
Onivyde Irinotecan Liposome Metastatic Pancreatic Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 27, 2017 January 5, 2018 PC0107-000
Tagrisso Osimertinib Non-Small Cell Lung Cancer (NSCLC) (first line) Reimburse with clinical criteria and/or conditions Notification to Implement Issued May 16, 2018 January 4, 2019 PC0137-000
Beleodaq Belinostat Withdrawn June 29, 2018 PC0139-000
Keytruda Pembrolizumab Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued April 21, 2016 November 3, 2016 PC0077-000
Alecensaro Alectinib Non-Small Cell Lung Cancer Do not reimburse Notification to Implement Issued October 3, 2016 May 4, 2017 PC0092-000
Blincyto (Resubmission) Blinatumomab Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Notification to Implement Issued February 24, 2017 August 31, 2017 PC0097-000
Venclexta Venetoclax Chronic Lymphocytic Leukemia Reimburse with clinical criteria and/or conditions Notification to Implement Issued July 10, 2017 March 2, 2018 PC0105-000
TBD Cabozantinib Withdrawn October 6, 2017 PC0123-000
Besponsa Inotuzumab Ozogamicin Acute Lymphoblastic Leukemia (ALL) Reimburse with clinical criteria and/or conditions Notification to Implement Issued November 13, 2017 July 6, 2018 PC0121-000
Pomalyst Pomalidomide Multiple Myeloma Reimburse with clinical criteria and/or conditions Notification to Implement Issued March 15, 2019 September 18, 2019 PC0165-000
Nerlynx Neratinib ERBB2-positive breast cancer Do not reimburse Notification to Implement Issued April 18, 2019 December 5, 2019 PC0172-000
Lynparza Olaparib Ovarian Cancer Do not reimburse Notification to Implement Issued April 1, 2016 September 29, 2016 PC0081-000
Cyramza Ramucirumab File-Closed Not Submitted PC0078-000
Adcetris Brentuximab Vedotin HL at high risk of relapse or progression post-ASCT Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 10, 2017 February 21, 2018 PC0116-000
Faslodex Fulvestrant Locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued July 17, 2017 February 1, 2018 PC0110-000
Rituxan Rituximab Acute Lymphoblastic Leukemia Do not reimburse Notification to Implement Issued February 13, 2017 August 31, 2017 PC0102-000
Cabometyx Cabozantinib Renal Cell Carcinoma (RCC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 17, 2018 February 20, 2019 PC0163-000
Xtandi Enzalutamide Non-metastatic castration-resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued September 24, 2018 March 26, 2019 PC0149-000
Adcetris (Resubmission) Brentuximab Vedotin Hodgkin lymphoma (HL) Do not reimburse Notification to Implement Issued August 27, 2018 March 7, 2019 PC0145-000
Blincyto Blinatumomab Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) Reimburse with clinical criteria and/or conditions Notification to Implement Issued August 31, 2018 April 4, 2019 PC0146-000
Alunbrig Brigatinib NSCLC Do not reimburse Notification to Implement Issued December 5, 2018 August 1, 2019 PC0167-000
Mvasi Bevacizumab mCRC NSCLC Biosimilar Final Biosimilar Dossier Issued October 3, 2018 PC0158-000
Libtayo Cemiplimab Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Reimburse with clinical criteria and/or conditions Notification to Implement Issued July 9, 2019 January 22, 2020 PC0187-000
Abraxane Nab-paclitaxel Notification to Implement Issued February 14, 2014 September 23, 2014 PC0037-000
Alimta Pemetrexed Notification to Implement Issued May 31, 2013 November 19, 2013 PC0027-000
Gazyva Obinutuzumab Notification to Implement Issued August 11, 2014 January 27, 2015 PC0041-000
Jakavi Ruxolitinib Notification to Implement Issued June 25, 2012 January 14, 2013 PC0012-000
Mekinist Trametinib Notification to Implement Issued May 6, 2013 October 22, 2013 PC0030-000
Proleukin Aldesleukin (IL-2) Notification to Implement Issued January 30, 2015 June 22, 2015 PC0051-000
Tafinlar Dabrafenib Notification to Implement Issued March 18, 2013 December 5, 2013 PC0025-000
Trisenox Arsenic Trioxide Notification to Implement Issued August 30, 2013 February 18, 2014 PC0033-000
Xalkori Crizotinib Notification to Implement Issued Original Submission Complete October 23, 2012 May 2, 2013 PC0017-000
Yervoy Ipilimumab Notification to Implement Issued August 15, 2014 December 22, 2014 PC0042-000
Zelboraf Vemurafenib Notification to Implement Issued December 6, 2011 June 1, 2012 PC0006-000
Avastin Bevacizumab Platinum Resistant Ovarian Cancer Reimburse with clinical criteria and/or conditions Notification to Implement Issued October 29, 2015 May 5, 2016 PC0066-000
Ibrance Palbociclib Suspended November 11, 2015 PC0068-000
Cyramza Ramucirumab Notification to Implement Issued April 15, 2015 October 29, 2015 PC0059-000
Iclusig Ponatinib Notification to Implement Issued March 13, 2015 October 1, 2015 PC0056 -000
Zydelig Idelalisib Notification to Implement Issued April 7, 2015 August 18, 2015 PC0057-000
Revlimid Lenalidomide Notification to Implement Issued May 4, 2015 December 3, 2015 PC0061-000
Keytruda Pembrolizumab Advanced non-small cell lung carcinoma (first line) Reimburse with clinical criteria and/or conditions Notification to Implement Issued December 12, 2016 August 23, 2017 PC0101-000
Avastin Bevacizumab Withdrawn December 16, 2016 PC0100-000
Lonsurf Trifluridine and Tipiracil mCRC Resubmission Do not reimburse Notification to Implement Issued January 21, 2019 August 29, 2019 PC0173-000
TBD Entrectinib Withdrawn July 29, 2019 PC0157-000
Keytruda Pembrolizumab Renal Cell Carcinoma (RCC) Notification to Implement Issued August 2, 2019 April 2, 2020 PC0185-000
Xtandi Enzalutamide mHSPC Notification to Implement Issued February 24, 2020 September 23, 2020 PC0209-000
Keytruda Pembrolizumab Not Filed
Erleada Apalutamide metastatic castration-sensitive prostate cancer (mCSPC) Notification to Implement Issued October 15, 2019 April 22, 2020 PC0200-000
Blincyto Blinatumomab MRD+ ALL Resubmission Notification to Implement Issued January 20, 2020 October 29, 2020 PC0204-000
Adcetris Brentuximab Vedotin Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) Notification to Implement Issued March 30, 2020 December 3, 2020 PC0213-000
Lynparza Olaparib Not Filed
Keytruda Pembrolizumab head and neck squamous cell carcinoma (HNSCC) Notification to Implement Issued May 1, 2020 December 22, 2020 PC0216-000
Sarclisa Isatuximab Multiple Myeloma Under Review August 17, 2020 PC0220-000
Lynparza Olaparib metastatic castration-resistant prostate cancer (mCRPC) Under Review September 22, 2020 PC0223-000
Inqovi Decitabine-Cedazuridine Myelodysplastic Syndromes (MDS) Under Review October 9, 2020 PC0228-000
Tafinlar and Mekinist Dabrafenib and Trametinib NSCLC BRAF V600 Under Review October 1, 2020 PC0226-000
Bavencio Avelumab Urothelial Carcinoma (UC) Under Review September 18, 2020 PC0225-000
Zejula Niraparib First Line OC Under Review September 21, 2020 PC0224-000